J. Indian Inst. Sci.
A Multidisciplinary Reviews Journal
ISSN: 0970-4140 Coden-JIISAD
© Indian Institute of Science 2023.

REVIEW ARTICLE

Emerging Diabetes Technologies: Continuous Glucose Monitors/Artificial Pancreases

Abdulhalim M. Almurashi[1,2], Erika Rodriguez[1] and Satish K. Garg[1]*

Abstract | Over the past decade there have been many advances in diabetes technologies, such as continuous glucose monitors (CGMs), insulin-delivery devices, and hybrid closed loop systems. Now most CGMs (Medtronic-Guardian, Dexcom-G6, and Abbott-Libre-2) have MARD values of < 10%, in contrast to two decades ago when the MARD used to be > 20%. In addition, the majority of the new CGMs do not require calibrations, and the latest CGMs last for 10–14 days. An implantable 6-months CGM by Eversense-3 is now approved in the USA and Europe. Recently, the FDA approved Libre 3 which provides real-time glucose values every minute. Even though it is approved as an iCGM it is not interoperable with automatic-insulin-delivery (AID) systems. The newer CGMs that are likely to be launched in the next few months in the USA include the 10–11 days Dexcom G7 (60% smaller than the existing G6), and the 7-days Medtronic Guardian 4. Most of the newer CGM have several features like automatic initialization, easy insertion, predictive alarms, and alerts. It has also been noticed that an arm insertion site might have better accuracy than abdomen or other sites, like the buttock for kids. Lag time between YSI and different sensors have been reported differently, sometimes it is down to 2–3 min; however, in many instances, it is still 15–20 min, especially when the rate of change of glucose is > 2 mg/min. We believe that in the next decade there will be a significant increase in the number of people who use CGM for their day-to-day diabetes care.

Keywords: *CGM, HCL, TIR, TAR, HbA1c, Hypoglycemia*

CGM: A device that measures glucose values in the subcutaneous space via a sensor and is transmitted to a receiver/smartphone.

Hybrid Closed Loop (HCL) Systems: An insulin pump able to deliver variable insulin dosages based on CGM values using an algorithm.

1 Introduction

The global prevalence of diabetes has continued to increase in the past several decades. Over 530 million people are currently living with diabetes worldwide[1]. Unfortunately, there has been a disproportional increase in diabetes prevalence in emerging economies; such as India, China, Middle East, and Southeast Asia[2]. Diabetes is also more prevalent amongst minorities and socio-economically disadvantaged individuals, such as, Black Americans, Native Americans, Asian Americans, and Latinx in the United States of America (USA)[3–6].

It is known that socio-economically disadvantaged and minorities do not receive similar diabetes care[7–10]. For example, many times minorities are not even presented with new technologies as an option to facilitate their diabetes care. Both type 1 diabetes (T1D) and type 2 diabetes (T2D) are increasing globally at a rate of about 4% per year[1,11,12]. In the USA, 35–40 million people have diabetes[13]; of which, between 1.5 and 3 million have T1D[14]. The increasing prevalence, as reported by IDF, has been in part due to a lack of registries in many parts of the world and availability of inadequate data[1].

[1] Barbara Davis Center for Diabetes, University of Colorado Denver, 1775 Aurora Ct, Rm 1324, Aurora, CO 80045, USA.
[2] Madinah Health Cluster, Madinah, Saudi Arabia.
**Satish.garg@cuanschutz.edu*

ABBOTT Exhibit 2026, Page 1 of 26
Dexcom, Inc. v. Abbott Diabetes Care Inc.
IPR2023-01251

Due to increasing prevalence of diabetes, the healthcare cost related to diabetes management has significantly increased in the past decade. For example, the total healthcare cost has increased to $4USD trillion per year. In the USA, the lifetime cost for managing a person with T1D is about $1.5USD million with a total cost of about $1.5USD trillion[15,16]. On an average, about 8% of the total healthcare expenditure is spent every year for diabetes management in the USA, which amounts to about $327USD billion annually[16]. About $1USD billion is spent on acute diabetes complications (diabetes ketoacidosis (DKA) and severe hypoglycemia (SH)). It is also been reported that about $800 billion USD is spent globally annually for type 2 diabetes management[17].

Recently, there has been a significant change in delivering diabetes care due to the COVID-19 pandemic since March of 2020. The development and rapid adoption of telehealth and virtual diabetes care has increased not only in the USA but throughout the world. It is expected that digital health expenditure in the next few years will outpace investments in other facets of diabetes care. The majority of this was facilitated by the availability of remote data through continuous glucose monitors (CGM), continuous subcutaneous insulin infusion (CSII or insulin pump), and hybrid closed-loop systems (HCL). In part, this was facilitated by the US Federal government's Food and Drug Administration (FDA) authorizing the availability of data from these emerging technologies to the patients and providers (temporarily, even across different States in the USA). It appears that telehealth is here to stay especially for ongoing diabetes management. As we have learned through the pandemic, one can deliver effective virtual care while initiating new technologies like CGM, insulin pumps, and HCL remotely.

Insulin Pump: A device that delivers insulin doses (basal and bolus).

It appears that about 150 million people require insulin therapy globally for their day-to-day diabetes management[18, 19]. About 30 million people have T1D globally and another 15–20% of people with T2D are misdiagnosed as they have positive antibodies (GAD, IAA, ICA, and ZnTr8), indicating beta-cell autoimmunity with slower onset of insulin dependence (T1D)[20]. In addition, 10–15% of patients with T2D will exhaust their beta-cell function during their lifetimes, as T2D diagnosis is occurring at an earlier age. Insulin-requiring patients will need close monitoring of their glucose levels so that their insulin dose can be manipulated safely. The CGM use, insulin pump therapy or a HCL, improves overall glucose control, especially reducing overnight hypoglycemia. However, less than 20–30% of T1D and less than 1% of T2D of insulin-requiring patients in the USA are on some sort of pump therapy[21]. Limited use is due to several barriers: cost, lack of knowledge, availability, and implementation challenges[22].

In the past three decades, there has been significant development of new technologies, newer non-insulin medications for T2D, and insulins for improving diabetes outcomes[23]. Due to all these advances, most people with T1D and T2D are living longer. It is not uncommon to see people with T1D living into their 8th or 9th decade of their lives[15,24]. In contrast, 40 years ago we were taught that the majority of T1D patients would not live beyond 30–40 years of age and most women were not allowed to conceive because of challenges in diabetes management and complications associated with pregnancy.

Despite advances in technologies and therapeutics, life expectancy is still reduced by 10–15 years in patients with T1D and T2D[25,26]. Generally, long-term diabetes complications have significantly decreased. However, the total number has risen due to an overall increase in prevalence. Recent data from the T1D Exchange in the US, Diabetes Registry in Germany (DPP), and SWEET Registry between US and Europe have shown that overall glucose control in patients with T1D is suboptimal despite an increase in the use of CGMs and insulin pumps[27]. Only about 1 out of 4 patients reach the American Diabetes Association (ADA) and the European Association of Study for Diabetes (EASD) target of glucose control (<7%) as measured by A1c.

2 Glucose Monitoring

2.1 Urine Monitoring and Self-Monitoring of Blood Glucose (SMBG)

More than 40 years ago, patients diagnosed with diabetes could only monitor their blood glucose levels indirectly by checking the amount of glucose present in their urine (glucosuria)[28]. About 35 years ago, SMBG became first available where patients would acquire blood from a fingerstick, which then could be placed on a test strip to get the glucose values[28]. Nearly four decades ago, many physicians were questioning the usability of SMBG in clinical practice. It was not uncommon to hear ***"Who?" "When?" and "Why?"*** from providers and patients. However, SMBG was first used successfully in a large clinical trial sponsored by the National Institutes of Health (NIH, Bethesda, MD); Diabetes Control

ABBOTT Exhibit 2026, Page 2 of 26
Dexcom, Inc. v. Abbott Diabetes Care Inc.
IPR2023-01251

and Complications Trial (DCCT)[29]. Since then, SMBG has been widely utilized for insulin-requiring patients to adjust their insulin dose and infrequently for patients with T2D not requiring insulin[30].

2.2 Continuous Glucose Monitoring (CGM)

In recent years, experts in diabetes have stressed the importance of CGM use, for improved glycemic outcomes[31–47]. What was commonly said about SMBG 35 years ago, was repeated two decades ago about CGM ***(Who? Why? When?)***[28]. However, there are now > 7 million CGM users worldwide, with a market cap of about $7USD billion at the time of this writing[48]. We believe that CGM will become the choice for glucose monitoring (replace SMBG) in clinical practice over the next 5–10 years in insulin-requiring patients with diabetes, assuming it is cost effective.

The first professional CGM was iPro, developed by MiniMed (now Medtronic Diabetes, Northridge, CA) in 1999[49]. The iPro collected continuous glucose data and after 3 days, the provider was able to download the data and adjust the patient's treatment accordingly. The earliest adjunctive real-time CGM (rtCGM) approved by the FDA was the GlucoWatch (GW) Biographer, developed about 24 years ago (Cygnus, Redwood City, CA)[31]. GW had a warm up period of 2 h and used reverse-iontophoresis to extract a small amount of interstitial fluid and measure glucose concentrations[32]. This data was displayed as a glucose value every 20 min on the GW for 12 h. When released, GW had a very high MARD (22%)[31,50]; whereas, most current CGMs have MARD values in the single digits (between 8 and 10%). Over the years several advancements in personal CGM devices included: better accuracy, increased duration of use, non-adjunctive, standalone, and decreased size.

The majority of CGMs measure glucose in the interstitial fluid every 1–5 min depending on the type of sensor[51]. These systems are considered personal (unmasked), where patients can access their glucose data in real-time. Or they can be professional (masked), where glucose values are downloaded and retrospectively reviewed in a clinic/research setting. Currently, patients with diabetes primarily utilize personal CGMs, and professional (retrospective) CGMs are rarely used; but are still utilized for research purposes.

A CGM can be worn on the skin or implanted subcutaneously[52,53]. Sensors can be real-time (rtCGM), where glucose values are transmitted to a receiver/smartphone continuously. Intermittently scanned CGMs (isCGM) require patients to scan with a receiver/smartphone. It is known that there is a lag period of 3–15 min between interstitial and blood glucose values depending on the device. Early CGMs required SMBG confirmation before user intervention (adjunctive)[31–44]. Newer CGMs data are used to make treatment decisions as standalone devices. Currently there are four major CGMs that are available and approved by the FDA in the USA: Medtronic, Dexcom (San Diego, CA), FreeStyle Libre (Alameda, CA), and Eversense (Senseonics, Baltimore, MD).

Medtronic introduced their Guardian CGM series in early 2000. Their first CGM was the Guardian REAL-Time system which provided glucose values every 5 min. Guardian 3 was an integrated CGM, that was only compatible with MiniMed insulin pumps[54,55]. Last year the Guardian 4 sensor was approved as a non-adjunctive CGM in Europe that can link to the 780G pump and the smart/memory insulin pen (Inpen)[56]. The Guardian 4 is currently not approved as an iCGM because of paracetamol interference and a MARD > 10%[57] (Fig. 1). The manufacturer has also been working on a new non-adjunctive 7-days CGM (Simplera formally known as Synergy) that combines both sensor and transmitter into one device like the Dexcom G7 and Libre 2 and 3[58]. Presently, Simplera has not been approved in the USA or Europe.

Dexcom has had many versions of CGMs. Initially, the Dexcom short-term sensor (STS) was approved in 2006 by the FDA as a 3-days adjunctive CGM. STS had higher MARD values, 16–25% when compared with SMBG and YSI[35]. A year later, the Dexcom SEVEN system was introduced which included 7 days of continuous wear and offered more convenience[59]. Subsequently, the introduction of the G4 PLATINUM in 2012 featured improved overall accuracy, especially in detection of hypoglycemia. The G4 expanded its' capabilities in 2015 by including a SHARE feature[60]. SHARE gave patients the ability to share their glucose data with up to five users. This feature allowed caretakers to remotely monitor glucose levels and offer treatment support. The same year, the G5 sensor was released, which incorporated wireless rapid data downloads on a smart phone and/or receiver[61]. The G6 was approved in 2018 as the first iCGM that allowed integration with different insulin pumps, such as Tandem and Omnipod 5[62,63]. In addition, iCGM doubled its' SHARE capabilities and increased wear time to 10 days[64,65]. The G7 iCGM is not yet approved

ABBOTT Exhibit 2026, Page 3 of 26
Dexcom, Inc. v. Abbott Diabetes Care Inc.
IPR2023-01251

Model	Guardian Real Time	iPro 2	Enlite	Guardian 3	Guardian 4
Year of FDA Approval	2005	2011	2016	2018	Not approved by FDA
MARD	17.2%	13.6% in adult 15% in pediatric	18.3%	8.7-9.14% in arm 9.6-10.5% in abdomen	10.6%
Wear Length Time	3 days	6 days	6 days	7 days	
Warm Up Time	2 hours	1 hour	2 hours		
Repeated Calibrations Needed	Every 12 hours	3-4 times a day	First day, every 6 hours. Afterwards, every 12 hours	Every 12 hours	No (Once the 1st day)
Measures Glucose	Every 5 minutes				
Wireless Data Sharing	N/A	N/A	N/A	5 people	
Alerts	N/A	N/A	N/A	Yes	
Transmitter Duration	12 months				
Interference With	Acetaminophen	Acetaminophen	None	Acetaminophen	Unknown
Pump Integration	N/A	N/A	Veo, MiniMed 530G,630G, & 670G	MiniMed 670G & 770G	MiniMed780G

Figure 1: Development of Medtronic's Guardian CGMs. Features of Guardian sensors over the years. The figure gives details of MARD, wear length time, warm-up time, calibrations needed, transmitter duration, wireless data sharing, and different drug interferences. Images taken at the Barbara Davis Center for Diabetes.

by the FDA but is available in Europe (EMA). The G7 is 60% smaller, lasts 10.5 days, and has a warm-up period of less than 30 min. G7 has the sensor and transmitter as one piece[66] (Fig. 2).

Abbott originally developed their Navigator 5-days adjunctive CGM[67]. Many years later a smaller, factory-calibrated version, called the FreeStyle Libre (isCGM) was launched initially in Europe and then in the USA[68]. When released, the Libre had a 1-h warm-up period. The Libre and Libre 2 are approved as a 14-days isCGM, that need to be scanned every 8 h. Libre 2 also includes alarms to notify the user of hypo- and hyperglycemic events[69, 70]. The Libre 3 has a 70% thinner profile (size of a penny) and is an rtCGM that was recently FDA approved in the USA (though not available freely in the USA); it relays glucose values every minute[71]. In Europe, the Libre 3 has been approved and used by investigators with an automatic insulin delivery (AID) system. Although the Libre 3 is approved as an iCGM in the USA, it is not allowed for AID use due to interference with aspirin and Vitamin C. The MARD reported at Advanced Technology and Therapeutics in Diabetes (ATTD) 2022 in Barcelona was 7.9%, though no data is available in published literature (Fig. 3).

There have been attempts for a longer-term implantable sensor. The first attempt at an implantable sensor was developed by Dexcom more than 24 years ago. It was the size of a AA battery that was implanted in the abdomen (subcutaneously). Only 15 patients were enrolled in a small pilot study[34]. The sensor had a high MARD value of 25% and did not last the intended 6 months. In addition, the sensor moved in the subcutaneous space, especially in obese individuals. As a result, the studies were terminated early, and the data was never submitted for FDA or EMA for approval.

It was not until 2018 that an implantable sensor was approved by both the FDA and EMA. Senseonics (Baltimore, MD) developed a smaller sensor, the Eversense® for 90-day wear[72]. The sensor insertion requires a surgical intervention under local anesthesia. The sensor is implanted in the upper arm and requires a transmitter to be replaced every 24 h that relays glucose values to a smart phone/receiver. This sensor is capable of vibratory alerts through the transmitter. Sensor duration up to 180 days with the Eversense XL was approved only in Europe. Eversense 3 (E3)

ABBOTT Exhibit 2026, Page 4 of 26
Dexcom, Inc. v. Abbott Diabetes Care Inc.
IPR2023-01251

Model	Short Term Sensor (STS)	Dexcom SEVEN PLUS	Dexcom G4	Dexcom G5	Dexcom G6	Dexcom G6 Pro	Dexcom G7
Year of FDA Approval	2006	2007	2012	2015	2019	2019	Not Approved
MARD	26%	16%	13%	9%	9%	9%	8.1% in arm 9.1% in abdomen
Wear Length Time	3 days	7days			10 days		10.5 days
Warm Up Time	2 hours						27 minutes
Repeated Calibrations Needed	Every 6 hours				No		
Measures Glucose	Every 5 minutes						
Wireless Data Sharing	N/A		5 people		10 people	N/A	10 people
Alerts	Only for hypoglycemia	Yes					
Transmitter Duration	6 months			3 months		1 month	10 days
Interference With	Aspirin Vitamin C	Acetaminophen	Acetaminophen Hydroxyurea		Hydroxyurea	Ascorbic Acid Salicylic Acid	Unknown
Pump Integration	N/A		Tandem		Tandem Omnipod 5	N/A	Unknown

Figure 2: Development of Dexcom's CGMs. Features of Dexcom sensors over the years. The figure gives details of MARD, wear length time, warm-up time, calibrations needed, transmitter duration, wireless data sharing, and different drug interferences. Images taken at the Barbara Davis Center for Diabetes.

Model	FreeStyle Libre Pro	FreeStyle Libre	FreeStyle Libre 2	FreeStyle Libre 3
Year of FDA Approval	2016	2017	2018	2022
MARD	12.3%	12%	9.5%	7.9%
Wear Length Time	14 days			
Warm Up Time	1 hour			
Repeated Calibrations Needed	None			
Measures Glucose	Every 15 minutes	Every 1 minute		
Wireless Data Sharing	N/A	20 people		
Alerts	N/A		Yes; when scanned	Yes
Transmitter Duration	14 days			
Interference With	Hydroxyurea	Vitamin C Aspirin		
Pump Integration	N/A			

Figure 3: Development of Abbot's FreeStyle Libre CGMs. Features of Freestyle Libre sensors over the years. The figure gives details of MARD, wear length time, warm-up time, calibrations needed, transmitter duration, wireless data sharing, and different drug interferences. Images taken at the Barbara Davis Center for Diabetes.

ABBOTT Exhibit 2026, Page 5 of 26
Dexcom, Inc. v. Abbott Diabetes Care Inc.
IPR2023-01251

Model	Dexcom Implantable Sensor	Eversense	Eversense XL	Eversense (E3)
Year of FDA Approval	Not approved by FDA	2018	Not approved by FDA	2022
MARD	16-25%	11.2%	11.6%	8.5%
Wear Length Time	3 months	90 days	180 days	180 days
Warm Up Time	N/A	24 hours		
Repeated Calibrations Needed	Every 12 hours			2 calibrations per day, for the first 21 days of wear. Then, every 24 hours.
Measures Glucose	Every 5 minutes			
Wireless Data Sharing	N/A	5 people		
Alerts	Yes			
Transmitter Duration	51-58 days	3 months	6 months	
Interference With	N/A	Tetracycline Mannitol		
Pump Integration	N/A			

Figure 4: Implantable CGMs. Features of implantable sensors over the years. The figure gives details of MARD, wear length time, warm-up time, calibrations needed, transmitter duration, wireless data sharing, and different drug interferences. Images taken at the Barbara Davis Center for Diabetes.

was approved by the FDA for 6-months use in adults in 2022[53]. E3 had already been approved as non-adjunctive by the EMA > 2 years ago. The E3 has sacrificial boronic acid which increased the life expectancy of the sensor. In preliminary studies, the E3 lasted the full 6 months in 90% of patients. The new E3 has improved accuracy with a MARD of 8.5%[53]. No AID studies have been conducted in the USA with the E3. The manufacturer is developing a 1-year implantable sensor (Fig. 4).

With improved accuracy, connectivity to insulin pumps, and improved insurance coverage, CGMs are increasingly adopted in clinical practice. At the time of enrollment the T1D Exchange Study (2010–2012) conducted in the USA, 7% of 25,833 patients were using a CGM[73]. The 5-year follow-up study reported that about 30% of those patients were now using a CGM[74]. The number of users is expected to increase exponentially in the next 5 years to about 15–20 million users.

The continued progression of CGMs have allowed for pump integration and compatibility between different manufactures. The FDA introduced a new category that allows expedited approval, called integrated/interoperable CGM (iCGM)[62]. CGM accuracy is assessed is by calculating the mean absolute relative difference (MARD) between paired glucose values from the CGM versus BG values from the Yellow Spring Instrument 2300 (YSI, CITY, OH). Lower MARD indicates better accuracy. iCGM approval requires CGM values to be within ± 15 mg/dL or ± 15%, 20/20%, 30/30%, and 40/40% of the YSI value[75]. For example, CGM values need to be within 15 mg/dL if BG is < 70 mg/dL, or within 15% if BG > 70 mg/dL, and so on. iCGM designation also requires no interference with paracetamol and/or vitamin C.

There are many limitations of A1c measurements (Table 1). It is still the gold standard for assessing long-term (1–3 months) diabetes control. Many international organizations like ADA, AACE, EASD, and ATTD now strongly recommend CGM use in patients with TID and those with T2D on multiple daily injections (MDI). CGM use in patients with diabetes have consistently shown improved time-in-range (TIR)[76], quality of life[77], glucose control (A1c)[78–85], decrease in DKA and hypoglycemia (Level 1 and Level 2). No DCCT like trials have been performed with CGMs, however, retrospective, and cross-sectional analysis have shown close correlation of TIR with micro- and macro vascular complications[76].

While the benefits of CGM use in T1D are well known, they are underutilized in patients with T2D on MDI. In a DIAMOND study of 148 patients with T2D on MDI, patients were randomized to a CGM or continued to use SMBG measurements. The CGM group improved their A1c by 0.3%, in comparison to the SMBG group[86]. Similar conclusions were made in the MOBILE study with 175 patients with T2D on basal insulin. Along with reduced hypoglycemia events, there was an overall reduction of A1c

ABBOTT Exhibit 2026, Page 6 of 26
Dexcom, Inc. v. Abbott Diabetes Care Inc.
IPR2023-01251

Table 1: Limitations of A1C. Limitations of using A1c values in a medical setting.
1. Does not detect hypoglycemia, hyperglycemia, and variability
2. Cannot be used for acute glycemic management plan
3. Does not reflect rapid changes of blood glucose
4. False high and low values of A1C in certain situations:
a. Hematologic conditions
• Anemia
• Accelerate erythrocyte turnover
• Thalassemia
• Sickle cell disease
• Reticulocytotic
• Hemolysis
b. Disease States
• HIV infection
• Uremia
• Hyperbilirubinemia
• Dyslipidemia
• Cirrhosis
• Hypothyroidism
c. Physiologic states
• Aging
• Pregnancy
d. Medical therapies
• Blood transfusion
• Hemodialysis
e. Drugs/medications
• Iron
• Erythropoietin
• Dapsone
• Trimethoprim
f. Miscellaneous
• Alcoholism
• Chronic kidney disease

by 0.4%[87]. CGM use has also been proven to be advantageous in patients with T2D that are using oral anti-hyperglycemic agents to manage their diabetes. However, CGM use in patients with T2D not requiring MDI is limited. This may be in part due to cost and insurance reimbursement challenges[88–93].

The CGM is used to assess glucose control and has built-in adjustable and predictive alarms/alerts for hyper- and hypo-glycemia. Different metrics include: TIR is 70–180 mg/dL, time-below-range (TBR) is < 70 mg/dL, time-above-range (TAR) is > 180 mg/dL, and time-in-tight-range (TITR) is 70–140 mg/dL (there is no consensus on TITR yet) (Table 2)[94]. 70% TIR usually represents an A1c of ~ 7%. Depending on the level of glucose control, a 5–10% change in TIR, may represent a 0.5% to 1% change in A1c[95]. The TIR goals may need to be modified for elderly, during pregnancy, toddlers, and high-risk individuals with diabetes (Fig. 5).

Additionally, these devices can be useful in managing diabetes in high-risk populations such as, toddlers, pregnant patients, the elderly, and patients with other comorbidities[97]. It is well known that elderly individuals with diabetes are at a higher risk of hypoglycemia[98]. CGM use can decrease occurrence of these events, which

ABBOTT Exhibit 2026, Page 7 of 26
Dexcom, Inc. v. Abbott Diabetes Care Inc.
IPR2023-01251

Table 2: Commonly used glucose metrics.

Keywords	Definitions	Interpretation
Standard Deviation (SD)	A measure of glucose excursions from the mean	Reflects fluctuations (high/low) from their mean glucose level <SD = More glucose excursions >SD = Less glucose excursions
Coefficient of variation (CV)	Divide the SD by the mean glucose and multiply by 100. Used to correct and calculate glycemic variability (GV), or fluctuations in glucose levels over time	Reflects how stable a patient's glucose levels are. Larger variability correlates with increased risk of hypoglycemia <CV = Poor glycemic control >CV = Good glycemic control CV<33% = Stable glucose levels
Mean Absolute Relative Difference (MARD: either ≥100 mg/dL glucose or all levels)	The mean absolute relative difference between all CGM numbers and matched reference values	Used to calculate the accuracy of a CGM sensor
Mean Absolute Deviation) (MAD: <100 mg/dL glucose)	The mean absolute deviation between each data value and the mean of a data set	Calculates the accuracy of a CGM within the hypoglycemia range
HbA1c	Reflects the mean glucose levels for the previous three months. Used for testing for and managing diabetes	Normal: Below 5.7% Prediabetes: 5.7–6.4% Diabetes: 6.5% or above Diabetes management goal: 7% or less
Time In Range (TIR)	The percentage of time that glucose levels are within the target range (generally 70-180 mg/dL) Can be calculated for patients utilizing a CGM or fingerstick BGs (if <4x/day)	It is used in conjunction with SD/CV variability to assess glycemic control Ideal TIR= 70%
Time Above Range (TAR) Level 1 Hyperglycemia Level 2 Hyperglycemia	The percentage of time glucose levels are above the target range, or hyperglycemia - Blood glucose > 180mg/dL - Blood glucose > 250mg/dL	- High glucose levels; needs monitoring - Very high glucose levels; requires immediate management
Time Below Range (TBR) Level 1 Hypoglycemia Level 2 Hypoglycemia	The time the percentage of blood glucose is below the target range, hypoglycemia - Blood glucose <70mg/dL - Blood glucose < 54mg/dL	- Mild hypoglycemia; needs monitoring - Moderate hypoglycemia; requires immediate management
Low blood glucose index (LBGI)	An established metric of hypoglycemia risk (<70 mg/dL)	Assess hypoglycemic risk
High blood glucose index (HBGI)	An established metric of hyperglycemia risk (<180 mg/dL)	Assess hyperglycemic risk

may improve diabetes outcomes as measured by A1c, GV as measured by SD or CV, and quality of life. Furthermore, CGM use has been shown to be particularly useful in pregnant patients with diabetes. For example, CONCEPTT was an international multi-center RCT that studied CGM efficacy in pregnant patients with T1D. The CONCEPTT study showed a significant reduction of patient hyperglycemia and, in turn, improved neonatal outcomes[99]. Lastly, even people with prediabetes can benefit from CGM use. Patients with prediabetes have elevated postprandial glucose levels and CGM use may induce behavioral change, thus possibly delaying the onset of diabetes[100,101] (Fig. 5).

Since the COVID-19 pandemic, CGM has been used in hospitalized patients. CGM devices have allowed health care professionals to remotely monitor glucose levels. This is particularly important in ICU patients where frequent glucose measurements are recommended[102]. On the other hand, in certain circumstances such as in whole body cryotherapy, it is required to do SMBG measurements to avoid sensor inaccuracies, due to associated hypoxia[103,104].

In summary, CGM has come a long way in the past 25 years. CGM's accuracy has increased over time. Most have single-digit MARD values and can be used as non-adjunctive devices without requiring any SMBG calibrations. These devices

ABBOTT Exhibit 2026, Page 8 of 26
Dexcom, Inc. v. Abbott Diabetes Care Inc.
IPR2023-01251



Figure 5: Blood glucose targets for different diabetes populations. Variable blood glucose targets specific to diabetes population. Data from: Kweon[96].

have also become more convenient due to their reduced sized and simple insertion devices. Users can share their data with family member and providers to guide therapeutic decisions. Overall, CGM use helps with early detection of T1D/T2D[97,100,101], improves glucose control, facilitates in-patient diabetes care, and enhances remote diabetes care through telehealth[102,105–107].

2.3 Insulin Pumps

In healthy individuals without diabetes, beta-cells of the pancreas, secrete insulin every minute in response to a rise in glucose values. Insulin is released directly into the liver for optimized glucose utilization. Physiologically, insulin is continuously secreted in small amounts to keep euglycemia, commonly referred to as basal insulin (long-acting). A burst of rapid-acting insulin is delivered based on food intake or to correct for high BG (bolus) after meals. Therapeutic goal in patients with diabetes has been to imitate normal insulin secretion[108].

Over the last three decades many rapid-acting insulin analogs (Lispro (Humalog), Aspart (Novolog, Fiasp), Glulisine (Apidra), Lispro-aabc (Lyumjev) have been made available that differ in pharmacokinetics and pharmacodynamics for insulin pump use[108]. Currently, human regular insulin is not approved for use in insulin pumps due to the risk of catheter occlusions, and as a result, higher risk of DKA[109].

As mentioned earlier, the DCCT compared intensive therapy, insulin pumps or MDI (3 or more daily injections), along with SMBG measurements vs. standard treatment (2 or less daily injections)[110]. The trial was terminated early due to the results being significantly positive in the intensively treated group. The DCCT established that maintaining glucose values within a specified range was key to reducing complications related to diabetes[110]. There was a significant reduction of all micro-vascular complications (diabetic kidney disease and diabetic retinopathy). Since the conclusion of the DCCT in 1993, intensive therapy has been the standard of care for management of T1D. Intensive therapy has shown similar benefits in non-insulin requiring patients with T2D. The United Kingdom Prospective Diabetes Study (UKPDS) studied 5102 patients with T2D and demonstrated that intensive therapy reduces overall diabetic-complications[111].

The first insulin pump was a large portable backpack developed by Kadish in 1963[112]. This prototype was an advanced closed-loop system that delivered insulin intravenously based on continuous blood glucose measurements. Unfortunately, it was impractical for day-to-day patient use. In 1974, Miles Laboratory (Elkhart, Indiana; USA) developed the first commercial inpatient pump, the Biostator[113]. However, outpatient use of this pump was not feasible due to its complexity and size. Two years later, Kamon engineered the first portable autosyringe insulin pump, known as the "Big Blue Brick"[112]. Due to its intricacy and bulkiness, they were only offered to patients awaiting pancreas transplants. These early CSII systems paved the way for the development of smaller and more sophisticated models.

Pacesetter Systems, now Medtronic MiniMed Inc., introduced the first miniaturized version of an insulin pump, the MiniMed 502[114,115]. This commercial pump allowed subcutaneous

ABBOTT Exhibit 2026, Page 9 of 26
Dexcom, Inc. v. Abbott Diabetes Care Inc.
IPR2023-01251

continuous delivery of small amounts of insulin. Depending on food intake, patients could administer a bolus of an insulin analog. Three years later, the smaller 504 model was released, but with the same software as the 502. However, the launch of the MiniMed 506 in 1992 included significant advancements that incorporated daily insulin totals and bolus insulin memory. These new features centered on glucose trend tracking which helped users understand what contributed to a certain correction[116].

Despite many improvements, patients expressed the desire to temporarily detach from their pump at the insertion site. Thus in 1996, the MiniMed 507 included a quick release. The 507 model also increased the programmable basal rate from 6 to 12. The 507C model released three years later, again upgraded these rates, from 12 to 48. Later that same year, the MiniMed 508 included a vibration alerts, child-lock, specific programmable delivery patterns, and a remote-control feature.

With every version, the physical features of MiniMed pumps were modified. In 2001, Medtronic acquired MiniMed and combined their advanced algorithm software with these pumps for improved diabetes care. A year later, the MiniMed Paradigm 511 system consisted of an insulin pump and a CGM data display. Glucose values could be transferred from a SMBG meter to the Paradigm 511 insulin pump. This allowed patients to easily record, track, and share their glucose data. When Medtronic released the MiniMed Paradigm 512 in 2003, it included these same features but with wireless glucose data transmission. Although the Paradigm system was able to receive glucose data and suggest corrections, it could not automatically deliver insulin.

Tandem Diabetes Care (San Diego, CA, USA) released their first insulin delivery system in 2012, the t:slim[117]. It was the first touch-screen insulin pump in the USA[118]. Tandem received FDA approval in 2015 to integrate Dexcom G4 data using Bluetooth technology.

A tubeless insulin pump was released by Insulet (Bedford, MA, USA) in 2015, called the Omnipod[119]. The original Omnipod system consisted of a Personal Diabetes Manger (PDM) and a disposable pump (Pod) that contained an insulin reservoir that lasted 3 days. When first released, the PDM was a handheld analysis device that could wirelessly deliver insulin. Three more versions with minor improvements of the Omnipod system were made. The Omnipod Dash in 2019 included smartphone connectivity via Bluetooth, the Omnipod DISPLAY. The Dash also included Omnipod VIEW, which gave parents and caregivers remote and real-time access to glucose data, and insulin history from their smartphone. Wireless communication between an insulin pump and CGM, became the expectation when developing these devices.

Other manufacturers of insulin pumps available for a limited time in the USA included: (a) Deltec Cozmo in 2002 (Smiths Medical, London, UK), but suspended its operation in 2009 due to financial reasons[120]. (b) The Animas Corporation (West Chester, PA, USA) manufactured two pumps, the Animas Vibe and the OneTouch Ping, but stopped production in 2017 due to the competitive insulin pump market and financial infeasibility[121]. (c) In 2003, Roche Diabetes Care, Inc. (Indianapolis, IN) acquired Disetronic and marketed a newly designed Accu-Chek Spirit 3 years later. Subsequently, the Accu-Chek Combo was released and consisted of an insulin pump and a Bluetooth connected SMBG meter. This gave the user full remote control over insulin delivery. It was made available in the USA in 2012, but discontinued production in 2017 due to lack of traction in the USA. Accu-Chek pump is still available in Europe, primarily in UK.[122] The new Accu-Chek Solo is a tubeless insulin pump (like Omnipod) that features no screen and wireless connectivity and is only available in some parts of Europe.

Several other insulin pumps have also been manufactured worldwide, with limited patient use. The Kaleido, manufactured by ViCentra (Utrecht, Netherlands), is the smallest commercially available insulin pump, but it is only offered in Europe[123]. It comes with two rechargeable and interchangeable patch pumps that permits insulin delivery via a Bluetooth enabled PDM (like Omnipod). Notably, the Kaleido is a combination pump; it has a patch pump, but it also has tubing for flexibility in pump location when wearing specific clothes- the user wears two separate adhesives to their skin. SOOIL Development Co., Ltd. (Seoul, Korea) produces the DANA insulin pumps, which allow for remote control insulin dosing through a users' smart phone[124]. The DANA system is currently only available for patients in Europe and Asia. In 2020, Ypsomed (Burgdorf, Sweden) announced a partnership with Eli Lilly and Company (Indianapolis, IN) to develop a closed loop system[125]. Presently, it is only available in Europe.

Most of the pumps used in the USA are made by: Medtronic MiniMed Inc., Tandem Diabetes Care Inc., and Insulet Corporation.

ABBOTT Exhibit 2026, Page 10 of 26
Dexcom, Inc. v. Abbott Diabetes Care Inc.
IPR2023-01251

2.4 Hybrid Closed-Loop Systems (HCL)

Unfortunately, at present there are no fully automated closed-loop systems available. Currently only HCL systems are approved for patients with diabetes. HCL is considered a hybrid system because it requires a patient to bolus insulin for carbohydrate (CHO) intake. An HCL system consist of an integrated insulin pump, CGM, and algorithm, to help sustain users at a desired glucose target. Many integrated HCL systems are now available. However, patients do not have the ability to customize and pair different insulin pumps, CGMs, and algorithms together. A fully automated closed-loop, or "bionic pancreas", might consist of a dual or triple hormone system (insulin, glucagon, and/or pramlintide)[126–128]. These new systems might include artificial intelligence to facilitate the algorithm that will automatically adjust to individual patient needs over time.

The MiniMed Paradigm REAL-Time system 515, released in 2006, was the first diabetes management system that combined insulin pump therapy with real-time updated glucose values every 5 min[129,130]. Due to differing regulations, the advanced MiniMed Veo which featured low-glucose suspend (LGS), was made available only in Europe in 2009[131]. This was the first LGS system, that suspended insulin delivery when glucose values reached a preset low value (40–110 mg/dL). Medtronic developed one more reiteration of the Paradigm system in the USA, the MiniMed Paradigm REAL-Time Revel 523. This combined system included CGM predictive alerts up to 30 min before hypoglycemia.

The MiniMed Veo was known as the 530G (MiniMed) in the USA in 2013. The 530G pump was integrated with a CGM that suspended insulin delivery using a preset modifiable low glucose range (60–90 mg/dL). When low glucose values were detected by the Enlite glucose (Medtronic, Northridge, CA) sensor, the 530G (also known as Threshold Suspend- TS) suspended insulin delivery for up to 2 h[132]. TS has been shown to significantly reduce hypoglycemic events. The ASPIRE in-clinic crossover study, where patients were randomized into LGS "on and off" (with a washout phase), supported this approval in the USA[133]. Patients spent significantly less time after exercise induced hypoglycemia in the in-clinic setting. Due to the cross-over design with this study, there was a spillover effect of hypoglycemia, commonly referred to as "hypoglycemia begets hypoglycemia". This was one of the most unethical studies because patients, although under close observation, had to stay in a hypoglycemic state for 4 h to verify that the TS feature worked effectively. During extended periods of insulin suspend for 4 h, counterregulatory hormones compensate and gluconeogenesis may raise the BG, which can lead to DKA (not observed in the ASPIRE in-clinic study)[134]. This study observation resulted in most future HCL studies avoiding a cross-over design.

A 3-months RCT, ASPIRE at home study was conducted to study 247 T1D adult patients with documented nocturnal hypoglycemia. This study evaluated the effects of changes in A1C and nocturnal hypoglycemia events when TS "on" or "off". Use of the TS system showed a 37% decrease in nocturnal hypoglycemia, in comparison to those using a sensor-augmented therapy without TS[135,136].

The launch of the 620G in 2014 was the first integrated insulin pump with a CGM launched in Japan. The continued evidence in support of TS systems lead to the release of the 630G in the USA, with the same algorithm as the 530G but with waterproofing, remote blousing, and the insulin on board (IOB) displayed on the screen. A year before, in 2015, the MiniMed 640G was made available outside the USA. The MiniMed 640G included "predictive low-glucose suspend" (PLGS) which predicted hypoglycemia (within 20 mg/dL) using a preset, and then stopped insulin delivery[137,138]. Although, never approved by the FDA, the 640G's PLGS system was useful in getting a HCL system (670G).

The first HCL system was the 670G, which included insulin suspension during hypoglycemia and automatic insulin delivery based on hyperglycemia[139–142]. This system allowed for personalized and automated basal insulin delivery[143]. It adjusted basal insulin based on a Proportional Integral Derivative (PID) algorithm system[144]. This algorithm changed the rate of insulin delivery based on how far from the glucose target is, and how much it has changed. This enabled the background insulin delivery needed to maintain a stable blood glucose value. To test this device, a single arm study was designed, as allowed by the FDA for faster approval processes because it only tested for safety. It was shown to significantly reduce hypoglycemia in patients with T1D[141,145]. The 670G was originally well-accepted by patients, however, due to repeated need for calibrations and multiple alarms, many patients discontinued device use[146].

In 2020, the MiniMed 770G was released using the same SmartGuard algorithm as the 670G but with added smartphone connectivity with possibility of shared data and increased user availability (age 2 and above). The MiniMed HCL

ABBOTT Exhibit 2026, Page 11 of 26
Dexcom, Inc. v. Abbott Diabetes Care Inc.
IPR2023-01251

Model	Medtronic 670G/ 770G	Medtronic 780G	Tandem t:slim X2 Basal-IQ	Tandem t:slim X2 Control-IQ	Omnipod 5
FDA Approval	2017/2020	Not yet approved	2018	2020	2022
CGM Used	Guardian 3	Guardian 3 or 4	G6		
Auto-Mode	After 48 hours		Immediately		
Basal adjusted	Every 2-6 days		Based on previous basal program		With each pad change
Target Range (mg/dL)	120	100, 110 or 120	N/A	112.5-160	110, 120, 130, 140, or 150
Correction Target (mg/dL)	Fixed at 150	Fixed at 120	N/A	Fixed at 110	Flexible
Modified Parameters	ICR DIA	ICR DIA	ICR ISF Basal Rate		ICR ISF DIA
Fixed Parameters	Basal Rate ICF	Basal Rate ICF	DIA is 5 Hours	DIA is 5 Hours Correction Target	Basal rate
Exercise Mode (mg/dL)	Temporary Target (150)	Exercise Mode (150)	N/A	Exercise Mode (140-160)	Activity Mode (150)
Sleep mode (mg/dL)	N/A	N/A	N/A	Sleep Mode (112.5-120)	N/A
Additional Features (mg/dL)	Recommended Bolus	Auto-Bolus	N/A	Extended Bolus Insulin Delivery	N/A
Upload program	CareLink		t: Connect		Glooko
Insulin Carb Ratio (ICR), Duration Insulin Action (DIA), Insulin Sensitivity Factor (ISF)					

Figure 6: Commonly used HCL systems (FDA and/or EMA Approved). Comparison of commonly used HCL systems. Images from the PANTHER Program and through the Barbara Davis Center for Diabetes.

system began auto-mode after 48 h, so that it can program its own basal insulin rates, updating every 2–6 days. Within the same year, 780G was released with an advanced SmartGuard algorithm which included the ability for correction boluses every 5 min[147]. It featured auto-bolus capabilities, flexible target ranges 100, 110 or 120 mg/dL, and an improved exercise mode[148]. Initial registration studies showed improved TIR and a decrease of hypoglycemic events, especially nocturnal[149]. Real-world studies supported these findings[150, 151]. Although offered internationally, the 780G is currently not approved by the FDA in the United States at the time of this writing[150] (Fig. 6).

The tandem X2 pump can be used with two systems, Basal or Control-IQ[152,153]. Both systems were capable of suspending insulin delivery if sensor glucose is < 70 mg/dL[154]. The algorithm used is Model Predictive Control (MPC) which analyzes CGM data to reduce the risk of hypoglycemia. It automatically stopped insulin delivery if glucose was predicted to be < 80 mg/dL within 30 min[154]. The user can also choose to upgrade their X2 pump from Basal-IQ to Control IQ through an online software update. The control-IQ system has an added feature that adjusts basal insulin rates based on preprogrammed settings. Unlike MiniMed, Tandem allows users to set their body weight and basal insulin settings, allowing immediate access to "Control-IQ" (Fig. 6).

Control-IQ has a feature that can correct for predicted hyperglycemia (> 180 mg/dL) by automatically delivering 60% of the insulin sensitivity factor (ISF) as a correction bolus every hour to maintain a glucose target (112–160 mg/dl)[155]. Like the 780G, the Control-IQ system has an "exercise" feature which decreased the basal rate to allow for a higher target. Control-IQ has additional features like sleep mode and extended

ABBOTT Exhibit 2026, Page 12 of 26
Dexcom, Inc. v. Abbott Diabetes Care Inc.
IPR2023-01251

bolus insulin delivery especially when high fat and protein meals are consumed[156].

A RCT using Control-IQ system showed increased TIR (>70%) in T1D patients, in both adult and pediatric age groups[155, 157–159]. The Control-IQ system was the first HCL that did not require finger calibrations to stay in an control-IQ; this made it easier for patients and clinicians. The 780G and the Control-IQ system are very similar, and many studies have compared the two[157,158,160]. However, the 780G was shown to be more effective in treating hyperglycemia; this may be since the 780G system adjusts insulin delivery every 5 min while Control-IQ adjusts every hour. In contrast, Control-IQ was shown to be more effective in hypoglycemia than 780G[160].

The Omnipod system includes a tubeless pump, a disposable pod, and a handheld Personal Diabetes Manager (PDM). The Pod contains an insulin reservoir that can hold up to 200 units of insulin and needs to be changed every 3 days. The Omnipod DASH was released in 2019 where CGM data was displayed on a PDM. The Omnipod system uses an MPC algorithm embedded in the Pod which communicates directly with a Dexcom CGM. A multicenter, inpatient feasibility study, showed that the Omnipod system was safe to use in adult, adolescent, and pediatric patients with T1D[161,162]. Although, the DASH permitted 12 different basal settings as well as a temp basal setting, it was not a HCL.

Omnipod 5 HCL was approved in 2022. Omnipod 5 is currently the only tubeless, AID system approved by the FDA. Like Tandem, Omnipod has an "automated mode feature that can be used without calibration. It adjusts insulin delivery based on data analytics for the last 72 h.[163] Omnipod and Tandem utilize the same MPC algorithm to adjust insulin delivery, every 5 min[164]. In contrast to MiniMed, Omnipod users can modify correction factors. The Omnipod system allows for up to 8 different glucose targets (110–150 mg/dL) in a day and allows small increments (10 mg/dL). The exercise mode is like other HCL systems. In a single arm study in pediatric patients, use of this AID system was safe and showed improved glycemic outcomes, increased TIR, and reduced hypoglycemia[163,165].The Omnipod is currently approved for patients with T1D above 2 years old[166]. All HCL systems revert to manual mode based on different safety parameters (Fig. 6).

There are many HCL algorithms currently not approved by the FDA. DBLG1 is a medical device company that customizes HCL systems with a self-learning algorithm between Dexcom and different insulin pumps (such as Roche Accu-Chek, ViCentra, Kaleido, SOOIL, and Cellnovo). It adjusts basal insulin delivery and corrects high glucose every 5 min. It also has Zen Mode for temporary targets. It requires weight, TDD, meal ratio, and basal rates to be entered. Entering the meal size instead of carb counting is a unique parameter. It was approved in Europe based on studies that showed improved glycemic control, increased TIR, and decreased hypoglycemia[167]. However, the DBLG1 system is currently not approved by the FDA.

CamAPS FX is an Android app that manages glucose levels in patients with T1D. The app is compatible with the YpsoPump, DANA Diabecare RS, and the DANA-I insulin pump. It uses the Cambridge control algorithm to automatically adjust insulin delivery every 12 min, based on Dexcom's G6 CGM readings[168]. This glucose data is uploaded to a universal diabetes management platform, Diasend or Glooko. A multicenter RCT study conducted on 86 T1D patients for 12 weeks documented improved glycemic control and decreased hypoglycemia for ages 6 years and older[169]. Although only approved in Europe, there is limited patient use in the USA.

At times, a system can be customized and built specifically for each unique user. These Do-It-Yourself (DIY) "artificial pancreas" systems (APS) are self-driven. Like commercial systems, they automatically adjust and control insulin dosing. Some examples of these systems include Open Artificial program system (OpenAPS) and the AndroidAPS; both utilize CGM readings (i.e. Dexcom or Medtronic Enlite) and a pump (Dana-RS) to make this possible. The community helps each other build their individualized system through these DIYAPS. Although these DIYAPS do not have any regulatory approvals, individuals are not prevented from using them[170–174].

The HCL systems approved by the FDA have all shown increased TIR with overall reduction of hypoglycemic events[175–179]. These systems also include higher glucose thresholds, allowing patients the ability to exercise without large fluctuations in glucose levels[140, 141, 148, 158]. Although none of these HCL systems are approved for use in patients with T1D associated with pregnancy, off-label use has shown improvement in glycemic control with improved maternal and fetal outcomes[99, 178, 180].

2.5 Smart Insulin Pen

Smart Insulin Pens: A reusable smart insulin injector that suggests and tracks dosing information via an app.

Due to the high cost of insulin pumps, most patients cannot afford them. As a result, many

ABBOTT Exhibit 2026, Page 13 of 26
Dexcom, Inc. v. Abbott Diabetes Care Inc.
IPR2023-01251

have turned to smart pens (Memory/connected pens). Smart pens are more affordable and have proven to be beneficial for patients on MDI therapy. These pens use CGM data to help users guide their diabetes management, determine recommended insulin bolus, insulin dose reminders, and track the insulin dose. Smart pens utilize a mobile app that can be downloaded by the provider or patient. Currently, only one smart pen has been approved by the FDA, the InPen (Medtronic, Northridge, CA)[181–183]. The Inpen connects to the Guardian 4 and the Dexcom G5/G6 and was recently approved in Europe (EMA). Many trials have shown improvement in A1c, increase in TIR, and patient satisfaction and adherence to treatment while using these pens[184, 185].

Many smart pens are currently in development: NovoPen 6, NovoPen Echo Plus (Novo Nordisk; Bagsværd, Denmark), Esyta (Emperra GmbH E-Health Technologies; Potsdam, Germany), Pendiq 2.0 (Pendiq GmbH; Moers, Germany), YpsoMate SmartPilot (YpsoMed Holding HG; Burgdorf, Switzerland), Vigipen (Diabnext; Switzerland), KiCoPen (Cambridge Consultants Ltd; Cambridge, UK), and the Eli Lilly tempo pen (Indianapolis, IN)[19, 186]. Some of these smart pens are already available in Europe. There is an attempt to standardize the reporting of smart pens, CGM data, and HCL systems so that the report appears like an EKG[187–189]. There are many platforms that are available to download these reports such as, Care Link, Glooko, Clarity, and Libre view.

An insulin pen cap is a lid that can be attached to all disposable insulin pens (basal and bolus insulin pens) and is able to transmit dosing data to an app[19]. Along with this, information from a CGM is used to recommend correction doses. In 2021 the FDA approved the Bigfoot Unity Diabetes Management System (Bigfoot Biomedical; Milpitas, CA) insulin pen cap for use with the Libre 2 CGM (for patients > 12 years of age)[190]. Other smart caps such as the Insulclock (Insulcloud, Spain) and Go Cap (Common sensing company) are approved by the FDA but have limited patient use[186]. These Insulin pen caps have shown early promise in better diabetes control in T1D and T2M[19, 185, 186].

2.6 Exercise, hypoglycemia in T1D

Exercise continues to pose a significant risk of hypoglycemia in insulin-requiring patients with diabetes; whether they are using insulin pumps or MDI with/without CGM[191]. It has been shown that a mini-dose of glucagon can reduce events of exercise-induced hypoglycemia, even without carbohydrate counting[127, 192–195]. Investigators from UMASS have been developing a dual-hormone (insulin and glucagon) pump system bionic pancreas, iLet (Beta Bionics; Concord, MA) where the second hormone is glucagon to help reduce this[196]. It is important to keep in mind that there is no glucagon preparation that has been approved for pump use in the USA or Europe. Recent development of a stable injectable glucagon molecule called zegalogue (dasiglucagon) by Zealand Pharmaceuticals (Copenhagen, Denmark) has been authorized for evaluation in a bionic pancreas system by Beta Bionics[197]. This September, Zealand Pharmaceuticals entered a global license and development agreement with Novo Nordisk to help salvage to launch of zegalogue. These dual-hormone systems are in early stages and currently not available for commercial use.

As mentioned above, Beta Bionics (iLet bionic pancreas, Concord, MA) has been doing several studies in developing a bionic pancreas which replicates a healthy pancreas insulin and glucagon delivery. A small pilot study published in NEJM about 8 years ago showed promising results of using insulin and glucagon delivery in a hybrid closed-loop system[198]. Just like many other HCL systems the TIR and TBR were significantly lower with two hormones delivered through two separate pumps based on the algorithm. It's important to note that no glucagon preparations have been approved by the FDA for continuous pump use. Long term effects of continuous glucagon use are also unknown. As expected beyond the complexity and increase in cost, in dual hormone models the amount of insulin needed was significantly higher than a single hormone (insulin alone) in the HCL system[199].

At the time of this writing, Beta Bionics have successfully completed several insulin-only configurations of their bionic pancreas (BP) in adults and pediatric patients with type 1 diabetes. The 13-weeks trial, conducted at 16 clinical sites across the United States, enrolled 326 participants ages 6–79 years who had T1D and had been using insulin for at least 1 year[200]. This randomized trial was sponsored by the National Institutes of Health (Bethesda, MD). Participants were randomly assigned to either a treatment group using the BP device or a standard-of-care control group using their personal pre-study insulin delivery method. All participants in the control group were provided with a continuous glucose monitor, and nearly one-third of the control group

ABBOTT Exhibit 2026, Page 14 of 26
Dexcom, Inc. v. Abbott Diabetes Care Inc.
IPR2023-01251

were using commercially available artificial pancreas technology during the study. This system is not approved in the USA (FDA) or in Europe (EMA). Their system does not require carbohydrate counting however patients are asked to enter the size of a meal to deliver the bolus of insulin for the meal[200]. There are five manuscripts that were recently published with BP system in randomized control trials[200–204]. The BP with insulin Aspart or insulin Lispro was shown to significantly improve A1c, TIR, and hyperglycemic metrics without increasing CGM measured hypoglycemia when compared with standard of care in adults and youth (ages 6–17 years) with T1D[202]. It is important to note that most of the studies with a BP system were short-term (13 weeks). The control arm included 32% of patients on MDI, 27% used a non-automated insulin pump, 5% used a pump with PLGS, and about 36% were using an approved HCL system before the study[201]. In addition, there was one study that reported results on using a faster-acting insulin Aspart (FIASP) within a BP in adults with T1D. They concluded that the use of Fiasp was no better than the reductions in A1c, TIR etc. observed with the BP using Aspart or Lispro[203]. Another study reported a 13-week extension of subjects who were randomized in the control arm who were allowed to use BP. The results concluded that the improvement in this extension study of BP was of similar magnitude to that observed in the RCT[204].

Hyperglycemic excursions especially after meals, even in HCL systems, continues to be a problem. One of the ways to mitigate hyperglycemia after meals is to use pramlintide to reduce these excursions[205, 206]. A study from researchers at Yale University proved that the use of pramlintide is possible in significantly reducing post-meal hyperglycemic excursions[207]. The biggest risk of using pramlintide in patients with T1D has been the risk of severe hypoglycemia[208,209]. This will need to be properly evaluated before it can be made available for clinical use. One day we could see a triple-hormone pump system that includes: insulin, glucagon, and pramlintide in an HCL system.

2.7 Inhaled (Afrezza) Insulin

Pulmonary delivery of insulin allows rapid onset of action with human regular insulin which is comparable to normal insulin action profile seen in healthy volunteers[210–212]. The first inhaled insulin, Exubera by Pfizer, was approved by the FDA in 2006[213]. Due to challenges in dose calculations and long-term unknown association of higher risk on lung cancer, its uptake was not good in the USA and was discontinued a year later[214]. The only pulmonary insulin available in the USA is Technosphere Insulin (TI), marketed as Afrezza (Mannkind Corporation, Westlake Village, CA, USA). TI has been shown to have a faster onset of action, but a shorter duration profile when compared to traditional rapid-action insulin analogs (Aspart, Lispro, or Glulisine)[215–217]. Many registration and other studies have shown its efficacy, lower hypoglycemia rates with tendency towards weight loss[218,219]. Due to the rapid onset of action but shorter duration of TI, studies have suggested higher insulin dose requirements[215, 216]. In many instances, second dose of inhaled insulin 1 or 2 h after meals may improve glycemic outcomes[215]. Some investigators in the USA have proposed correction boluses with inhaled insulin in patients using insulin pump or HCL users for rapidly correcting post-meal glucose excursions (off-label use)[220]. However, inhaled insulin dose is not accounted for in the total daily insulin dose for pump or HCL users.

2.8 Adjunctive Therapies

There has been recent interest in using SGLT1 and SGLT2-inhibitors in insulin-requiring patients with T1D. Some SGLT2-inhibitors have been approved in Europe for T1D; however, none of them have been approved in the USA because of DKA risks[221,222]. Regardless, their use in T2D has shown remarkable improvement in diabetic kidney disease and cardiovascular disease associated with diabetes[223–226]. Unless we have continuous ketone measurements (CKM) available (many companies are working adding CKM to CGMs)[227], it is hard to imagine that regulators especially in the USA will approve the use of SGLT2-inhibitors in T1D.

3 Conclusion

The technological and therapeutic advances in the field of diabetes over the last three decades has allowed patients to live longer and healthier lives[228, 229]. Quality and longevity of life has improved in patients with T1D/T2D, while simultaneously reducing overall diabetes burden. Implementation of CGMs, insulin pumps, and HCL systems, independently or in combination, have shown improved glucose control as measured by A1c and TIR[230,231]. Use of these technologies has shown significant reduction of long-term micro- and macrovascular complications and

ABBOTT Exhibit 2026, Page 15 of 26
Dexcom, Inc. v. Abbott Diabetes Care Inc.
IPR2023-01251

hypoglycemic excursions and facilitated remote virtual care for patients with diabetes.

Abbreviations

AID: Automated insulin delivery; A1C: Glycated hemoglobin.; APS: Artificial program system; ASPIRE: Automation to stimulate pancreatic insulin response; BGL: Blood glucose level; BP: Bionic pancreas; CGM: Continuous glucose monitors; CSII or insulin pump: Continuous subcutaneous insulin infusion; DCCT: Diabetes Control and Complications Trial; DPI: Derivative proportional integral; DKA: Diabetic ketoacidosis; FDA: U.S. Food and Drug Administration; FGM: Flash Glucose Monitoring; FIASP: Faster-acting insulin Aspart; GLP1: Glucagon like peptide 1 analog; GMI: Glucose management indicator.; GV: Glucose variability; GW: GlucoWatch; HCL: Hybrid closed-loop system; HBGI: High Blood Glucose Index; iCGM: Interoperable continuous glucose monitor; isCGM: Intermittently scanned continuous glucose monitoring; LBGI: Low Blood Glucose Index; LGS: Low glucose suspend; MAD: Mean absolute deviation; MARD: Mean absolute relative difference; MDI: Multiple daily injections; MPC: Model predictive control; PID: Proportional integral derivative; PDM: Personal diabetes management; PLGS: Predictive low glucose suspend; RCT: Randomized Controlled Trial; RT-CGM: Real-time CGM; R-CGM: Retrospective CGM; SBA: Sacrificial boronic acid; SD: Standard deviation; SGLTi: Sodium-glucose linked transporter inhibitor; SH: Severe hypoglycemia; SMBS: Self-monitoring blood sugar; STS: Short term sensor; TI: Technosphere insulin; T1D: Type 1 Diabetes; T2D: Type 2 diabetes; TAR: Time above range; TBR: Time below range; TIR: Time in range; TDD: Total daily dose; UKPDS: United Kingdom prospective diabetes study; YSI: Yellow Spring Instrument.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Declarations

Conflict of interest

Related to this manuscript, there are no conflicts of interest for all three authors.

Received: 18 October 2022 Accepted: 4 November 2022
Published online: 28 March 2023

References

1. Federation, I.D. *IDF Diabetes Atlas*. 2021. https://www.diabetesatlas.org.
2. Ramachandran A et al (2012) Trends in prevalence of diabetes in Asian countries. World J Diabetes 3(6):110–117. https://doi.org/10.4239/wjd.v3.i6.110
3. Link CL, McKinlay JB (2009) Disparities in the prevalence of diabetes: Is it race/ethnicity or socioeconomic status? Results from the Boston Area Community Health (BACH) survey. Ethn Dis 19(3):288–292
4. Beckles GL, Chou CF (2016) Disparities in the prevalence of diagnosed diabetes—United States, 1999–2002 and 2011–2014. Morbidity Mortality Weekly Report 65(45):1265–1269. https://doi.org/10.15585/mmwr.mm6545a4
5. Wilf-Miron R et al (2010) Disparities in diabetes care: role of the patient's socio-demographic characteristics. BMC Public Health 10:729. https://doi.org/10.1186/1471-2458-10-729
6. Lado JJ, Lipman TH (2016) Racial and ethnic disparities in the incidence, treatment, and outcomes of youth with type 1 diabetes. Endocrinol Metab Clin North Am 45(2):453–461. https://doi.org/10.1016/j.ecl.2016.01.002
7. Addala A et al (2021) A decade of disparities in diabetes technology use and HbA(1c) in pediatric type 1 diabetes: a transatlantic comparison. Diabetes Care 44(1):133–140. https://doi.org/10.2337/dc20-0257
8. Agarwal S et al (2021) Racial-ethnic disparities in diabetes technology use among young adults with type 1 diabetes. Diabetes Technol Ther 23(4):306–313. https://doi.org/10.1089/dia.2020.0338
9. McKergow E et al (2017) Demographic and regional disparities in insulin pump utilization in a setting of universal funding: a New Zealand nationwide study. Acta Diabetol 54(1):63–71. https://doi.org/10.1007/s00592-016-0912-7
10. Agarwal S, Simmonds I, Myers AK (2022) The use of diabetes technology to address inequity in health outcomes: limitations and opportunities. Curr Diab Rep 22(7):275–281. https://doi.org/10.1007/s11892-022-01470-3
11. Maahs DM et al (2010) Epidemiology of type 1 diabetes. Endocrinol Metab Clin North Am 39(3):481–497. https://doi.org/10.1016/j.ecl.2010.05.011

ABBOTT Exhibit 2026, Page 16 of 26
Dexcom, Inc. v. Abbott Diabetes Care Inc.
IPR2023-01251

12. Patterson CC et al (2012) Trends in childhood type 1 diabetes incidence in Europe during 1989–2008: evidence of non-uniformity over time in rates of increase. Diabetologia 55(8):2142–2147. https://doi.org/10.1007/s00125-012-2571-8
13. CDC (2020) National diabetes statistics report 2020: estimates of diabetes and its burden in the United States. Centers for Disease Control and Prevention. p. 2
14. States, E.o.D.a.I.B.i.t.U. (2020) Estimates of diabetes and its burden in the United States
15. Sussman M et al (2020) Estimated lifetime economic burden of type 1 diabetes. Diabetes Technol Ther 22(2):121–130. https://doi.org/10.1089/dia.2019.0398
16. Association AD (2018) Economic costs of diabetes in the U.S. in 2017. Diabetes Care 41(5):917–928. https://doi.org/10.2337/dci18-0007
17. Ranđelović S, Bipat R (2021) A review of coumarins and coumarin-related compounds for their potential antidiabetic effect. Clin Med Insights Endocrinol Diabetes 14:11795514211042024. https://doi.org/10.1177/11795514211042023
18. Garg SK, Rewers AH, Akturk HK (2018) Ever-increasing insulin-requiring patients globally. Diabetes Technol Ther 20(S2):S21-s24. https://doi.org/10.1089/dia.2018.0101
19. Masierek M et al (2022) The review of insulin pens-past, present, and look to the future. Front Endocrinol (Lausanne) 13:827484. https://doi.org/10.3389/fendo.2022.827484
20. Zaharieva ET et al (2017) Prevalence of positive diabetes-associated autoantibodies among type 2 diabetes and related metabolic and inflammatory differences in a sample of the Bulgarian population. J Diabetes Res 2017:9016148. https://doi.org/10.1155/2017/9016148
21. van den Boom L et al (2019) Temporal trends and contemporary use of insulin pump therapy and glucose monitoring among children, adolescents, and adults with type 1 diabetes between 1995 and 2017. Diabetes Care 42(11):2052. https://doi.org/10.2337/dc19-0345
22. Gajewska KA et al (2021) Barriers and facilitators to accessing insulin pump therapy by adults with type 1 diabetes mellitus: a qualitative study. Acta Diabetol 58(1):93–105. https://doi.org/10.1007/s00592-020-01595-5
23. Deeb LC (2008) Diabetes technology during the past 30 years: a lot of changes and mostly for the better. Diabetes Spectrum 21(2):78–83. https://doi.org/10.2337/diaspect.21.2.78
24. Distiller LA (2014) Why do some patients with type 1 diabetes live so long? World J Diabetes 5(3):282–287. https://doi.org/10.4239/wjd.v5.i3.282
25. Rawshani A et al (2017) Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med 376(15):1407–1418. https://doi.org/10.1056/NEJMoa1608664
26. Huo L et al (2016) Life expectancy of type 1 diabetic patients during 1997–2010: a national Australian registry-based cohort study. Diabetologia 59(6):1177–1185. https://doi.org/10.1007/s00125-015-3857-4
27. Miller KM et al (2015) Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care 38(6):971–978. https://doi.org/10.2337/dc15-0078
28. Hirsch IB (2018) Introduction: history of glucose monitoring. In: Role of Continuous Glucose Monitoring in Diabetes Treatment. American Diabetes Association: Arlington (VA). p. 1. https://doi.org/10.2337/db20181-1
29. Group, T.D.R. (1986) The Diabetes Control and Complications Trial (DCCT): design and methodologic considerations for the feasibility phase. Diabetes 35(5):530–545. https://doi.org/10.2337/diab.35.5.530
30. Schnell O et al (2015) Clinical utility of SMBG: recommendations on the use and reporting of SMBG in clinical research. Diabetes Care 38(9):1627–1633. https://doi.org/10.2337/dc14-2919
31. Garg SK et al (1999) Correlation of fingerstick blood glucose measurements with GlucoWatch biographer glucose results in young subjects with type 1 diabetes. Diabetes Care 22(10):1708–1714. https://doi.org/10.2337/diacare.22.10.1708
32. Tamada JA et al (1999) Noninvasive glucose monitoring: comprehensive clinical results. Cygnus Research Team. JAMA 282(19):1839–1844. https://doi.org/10.1001/jama.282.19.1839
33. Chase HP et al (2003) Use of the GlucoWatch biographer in children with type 1 diabetes. Pediatrics 111(4 Pt.1):790–794. https://doi.org/10.1542/peds.111.4.790
34. Garg SK, Schwartz S, Edelman SV (2004) Improved glucose excursions using an implantable real-time continuous glucose sensor in adults with type 1 diabetes. Diabetes Care 27(3):734–738. https://doi.org/10.2337/diacare.27.3.734
35. Garg S et al (2006) Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care 29(1):44–50. https://doi.org/10.2337/diacare.29.01.06.dc05-1686
36. Garg S, Jovanovic L (2006) Relationship of fasting and hourly blood glucose levels to HbA1c values: safety, accuracy, and improvements in glucose profiles obtained using a 7-day continuous glucose sensor. Diabetes Care 29(12):2644–2649. https://doi.org/10.2337/dc06-1361
37. Bailey TS, Zisser HC, Garg SK (2007) Reduction in hemoglobin A1C with real-time continuous glucose monitoring: results from a 12-week observational study. Diabetes Technol Ther 9(3):203–210. https://doi.org/10.1089/dia.2007.0205
38. Garg SK et al (2007) Continuous home monitoring of glucose: improved glycemic control with real-life use of

ABBOTT Exhibit 2026, Page 17 of 26
Dexcom, Inc. v. Abbott Diabetes Care Inc.
IPR2023-01251

continuous glucose sensors in adult subjects with type 1 diabetes. Diabetes Care 30(12):3023–3025. https://doi.org/10.2337/dc07-1436
39. Ellis SL et al (2007) Use of continuous glucose monitoring to improve diabetes mellitus management. Endocrinol Metab Clin North Am 36(Suppl 2):46–68. https://doi.org/10.1016/s0889-8529(07)80011-9
40. Garg SK (2009) The future of continuous glucose monitoring. Diabetes Technol Ther 11(Suppl 1):S1–S3. https://doi.org/10.1089/dia.2008.0105
41. Rodbard D et al (2009) Improved quality of glycemic control and reduced glycemic variability with use of continuous glucose monitoring. Diabetes Technol Ther 11(11):717–723. https://doi.org/10.1089/dia.2009.0077
42. Garg SK, Voelmle MK, Gottlieb P (2009) Feasibility of 10-day use of a continuous glucose-monitoring system in adults with type 1 diabetes. Diabetes Care 32(3):436–438. https://doi.org/10.2337/dc08-1745
43. Blevins TC et al (2010) Statement by the American Association of Clinical Endocrinologists Consensus Panel on continuous glucose monitoring. Endocr Pract 16(5):730–745. https://doi.org/10.4158/ep.16.5.730
44. Garg SK et al (2011) Use of continuous glucose monitoring in subjects with type 1 diabetes on multiple daily injections versus continuous subcutaneous insulin infusion therapy: a prospective 6-month study. Diabetes Care 34(3):574–579. https://doi.org/10.2337/dc10-1852
45. Moser EG, Morris AA, Garg SK (2012) Emerging diabetes therapies and technologies. Diabetes Res Clin Pract 97(1):16–26. https://doi.org/10.1016/j.diabres.2012.01.027
46. Garg SK (2008) Glucose monitoring: an important tool for improving glucose control and reducing hypoglycemia. Diabetes Technol Therapeutics 10:S-1(4)
47. Garg SK, Hoff HK, Chase HP (2004) The role of continuous glucose sensors in diabetes care. Endocrinol Metab Clin North Am 33(1):163–173. https://doi.org/10.1016/j.ecl.2004.01.001
48. Close KL (2022) CGM users worldwide. Close Concerns
49. Gross TM et al (2000) Performance evaluation of the MiniMed continuous glucose monitoring system during patient home use. Diabetes Technol Ther 2(1):49–56. https://doi.org/10.1089/152091500316737
50. Tierney MJ et al (2001) Clinical evaluation of the GlucoWatch biographer: a continual, non-invasive glucose monitor for patients with diabetes. Biosens Bioelectron 16(9–12):621–629. https://doi.org/10.1016/s0956-5663(01)00189-0
51. Reddy N, Verma N and Dungan K (2000) Monitoring technologies—continuous glucose monitoring, mobile technology, biomarkers of glycemic control. In: Feingold KR, et al. (eds) Endotext.MDText.com, Inc.: South Dartmouth (MA)
52. Rodbard D (2017) Continuous glucose monitoring: a review of recent studies demonstrating improved glycemic outcomes. Diabetes Technol Ther 19(S3):S25-s37. https://doi.org/10.1089/dia.2017.0035
53. Garg SK et al (2022) Evaluation of accuracy and safety of the next-generation up to 180-day long-term implantable eversense continuous glucose monitoring system: the PROMISE study. Diabetes Technol Ther 24(2):84–92. https://doi.org/10.1089/dia.2021.0182
54. Lal RA et al (2019) One year clinical experience of the first commercial hybrid closed-loop system. Diabetes Care 42(12):2190–2196. https://doi.org/10.2337/dc19-0855
55. Christiansen MP et al (2017) Accuracy of a fourth-generation subcutaneous continuous glucose sensor. Diabetes Technol Ther 19(8):446–456. https://doi.org/10.1089/dia.2017.0087
56. Whooley S (2021) Medtronic wins CE mark for smart insulin pen, Guardian 4 sensor. 2021. Available from: https://www.drugdeliverybusiness.com/medtronic-wins-ce-mark-for-smart-insulin-pen-cgm-system/
57. Kovatchev BP et al (2015) Assessing sensor accuracy for non-adjunct use of continuous glucose monitoring. Diabetes Technol Ther 17(3):177–186. https://doi.org/10.1089/dia.2014.0272
58. Whooley S (2022) Medtronic CEO confirms FDA warning could affect approval timing for next-gen diabetes tech. https://www.drugdeliverybusiness.com/medtronic-ceo-confirms-fda-warning-affects-approval-timing-for-next-gen-diabetes-tech-updates-on-pipeline/
59. Zisser HC et al (2009) Accuracy of the SEVEN continuous glucose monitoring system: comparison with frequently sampled venous glucose measurements. J Diabetes Sci Technol 3(5):1146–1154. https://doi.org/10.1177/193229680900300519
60. Nakamura K, Balo A (2015) The accuracy and efficacy of the Dexcom G4 platinum continuous glucose monitoring system. J Diabetes Sci Technol 9(5):1021–1026. https://doi.org/10.1177/1932296815577812
61. Link M et al (2021) Comparative accuracy analysis of a real-time and an intermittent-scanning continuous glucose monitoring system. J Diabetes Sci Technol 15(2):287–293. https://doi.org/10.1177/1932296819895022
62. Administration, U.S.F.D. (2018) FDA authorizes first fully interoperable continuous glucose monitoring system, streamlines review pathway for similar devices, U.S.F.D. Administration, Editor., FDA
63. Administration, U.S.F.D. (2018) De Novo request for classification of the Dexcom G6 continuous glucose monitoring system: results, U.S.F.D. Administration, Editor. FDA
64. Wadwa RP et al (2018) Accuracy of a factory-calibrated, real-time continuous glucose monitoring system during 10 days of use in youth and adults with diabetes.

ABBOTT Exhibit 2026, Page 18 of 26
Dexcom, Inc. v. Abbott Diabetes Care Inc.
IPR2023-01251

Diabetes Technol Ther 20(6):395–402. https://doi.org/10.1089/dia.2018.0150

65. Shah VN et al (2018) Performance of a factory-calibrated real-time continuous glucose monitoring system utilizing an automated sensor applicator. Diabetes Technol Ther 20(6):428–433. https://doi.org/10.1089/dia.2018.0143
66. Garg SK et al (2022) Accuracy and safety of Dexcom G7 continuous glucose monitoring in adults with diabetes. Diabetes Technol Ther. https://doi.org/10.1089/dia.2022.0011
67. Weinstein RL et al (2007) Accuracy of the 5-day FreeStyle Navigator Continuous Glucose Monitoring System: comparison with frequent laboratory reference measurements. Diabetes Care 30(5):1125–1130. https://doi.org/10.2337/dc06-1602
68. Blum A (2018) Freestyle libre glucose monitoring system. Clin Diabetes 36(2):203–204. https://doi.org/10.2337/cd17-0130
69. Wysham CH, Kruger DF (2021) Practical considerations for initiating and utilizing flash continuous glucose monitoring in clinical practice. J Endocr Soc 5(9):bvab064. https://doi.org/10.1210/jendso/bvab064
70. Alva S et al (2022) Accuracy of a 14-day factory-calibrated continuous glucose monitoring system with advanced algorithm in pediatric and adult population with diabetes. J Diabetes Sci Technol 16(1):70–77. https://doi.org/10.1177/1932296820958754
71. Whooley S (2022) FDA clears Abbott's next-gen FreeStyle Libre 3 14-day CGM. 2022. https://www.drugdeliverybusiness.com/fda-abbott-next-gen-freestyle-libre-3-cgm/#:~:text=BTIG%20analyst%20Marie%20Thibault%20pointed,with%20automated%20insulin%20delivery%20systems
72. Tweden KS et al (2020) Longitudinal analysis of real-world performance of an implantable continuous glucose sensor over multiple sensor insertion and removal cycles. Diabetes Technol Ther 22(5):422–427. https://doi.org/10.1089/dia.2019.0342
73. Beck RW et al (2012) The T1D exchange clinic registry. J Clin Endocrinol Metab 97(12):4383–4389. https://doi.org/10.1210/jc.2012-1561
74. Foster NC et al (2019) State of type 1 diabetes management and outcomes from the T1D exchange in 2016–2018. Diabetes Technol Ther 21(2):66–72. https://doi.org/10.1089/dia.2018.0384
75. Freckmann G et al (2019) Measures of accuracy for continuous glucose monitoring and blood glucose monitoring devices. J Diabetes Sci Technol 13(3):575–583. https://doi.org/10.1177/1932296818812062
76. Beck RW et al (2019) Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care 42(3):400–405. https://doi.org/10.2337/dc18-1444
77. Charleer S et al (2019) Quality of life and glucose control after 1 year of nationwide reimbursement of intermittently scanned continuous glucose monitoring in adults living with type 1 diabetes (FUTURE): a prospective observational real-world cohort study. Diabetes Care 43(2):389–397. https://doi.org/10.2337/dc19-1610
78. Lind M et al (2017) Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA 317(4):379–387. https://doi.org/10.1001/jama.2016.19976
79. Aleppo G et al (2017) REPLACE-BG: a randomized trial comparing continuous glucose monitoring with and without routine blood glucose monitoring in adults with well-controlled type 1 diabetes. Diabetes Care 40(4):538–545. https://doi.org/10.2337/dc16-2482
80. Beck RW et al (2017) Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA 317(4):371–378. https://doi.org/10.1001/jama.2016.19975
81. Battelino T et al (2012) The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia 55(12):3155–3162. https://doi.org/10.1007/s00125-012-2708-9
82. Group, J.D.R.F.C.G.M.S. (2009) Effectiveness of continuous glucose monitoring in a clinical care environment: evidence from the juvenile diabetes research foundation continuous glucose monitoring (JDRF-CGM) trial. Diabetes Care 33(1):17–22. https://doi.org/10.2337/dc09-1502
83. Charleer S et al (2018) Effect of continuous glucose monitoring on glycemic control, acute admissions, and quality of life: a real-world study. J Clin Endocrinol Metab 103(3):1224–1232. https://doi.org/10.1210/jc.2017-02498
84. Campbell FM et al (2018) Outcomes of using flash glucose monitoring technology by children and young people with type 1 diabetes in a single arm study. Pediatr Diabetes 19(7):1294–1301. https://doi.org/10.1111/pedi.12735
85. Bolinder J et al (2016) Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet 388(10057):2254–2263. https://doi.org/10.1016/s0140-6736(16)31535-5
86. Beck RW et al (2017) Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med 167(6):365–374. https://doi.org/10.7326/m16-2855
87. Martens T et al (2021) Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: a randomized clinical trial. JAMA 325(22):2262–2272. https://doi.org/10.1001/jama.2021.7444

ABBOTT Exhibit 2026, Page 19 of 26
Dexcom, Inc. v. Abbott Diabetes Care Inc.
IPR2023-01251

88. Gilbert TR et al (2021) Change in Hemoglobin A1c and quality of life with real-time continuous glucose monitoring use by people with insulin-treated diabetes in the landmark study. Diabetes Technol Ther 23(S1):S35-s39. https://doi.org/10.1089/dia.2020.0666
89. Wright EE Jr et al (2021) Use of flash continuous glucose monitoring is associated with A1C reduction in people with type 2 diabetes treated with basal insulin or noninsulin therapy. Diabetes Spectr 34(2):184–189. https://doi.org/10.2337/ds20-0069
90. Wada E et al (2020) Flash glucose monitoring helps achieve better glycemic control than conventional self-monitoring of blood glucose in non-insulin-treated type 2 diabetes: a randomized controlled trial. BMJ Open Diabetes Res Care. https://doi.org/10.1136/bmjdrc-2019-001115
91. Haak T et al (2017) Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther 8(1):55–73. https://doi.org/10.1007/s13300-016-0223-6
92. Bergenstal RM et al (2022) Randomized comparison of self-monitored blood glucose (BGM) versus continuous glucose monitoring (CGM) data to optimize glucose control in type 2 diabetes. J Diabetes Complic 36(3):108106. https://doi.org/10.1016/j.jdiacomp.2021.108106
93. Roussel R et al (2021) Important drop in rate of acute diabetes complications in people with type 1 or type 2 diabetes after initiation of flash glucose monitoring in France: the RELIEF study. Diabetes Care 44(6):1368–1376. https://doi.org/10.2337/dc20-1690
94. Battelino T et al (2019) Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care 42(8):1593–1603. https://doi.org/10.2337/dci19-0028
95. Beck RW et al (2019) The relationships between time in range, Hyperglycemia metrics, and HbA1c. J Diabetes Sci Technol 13(4):614–626. https://doi.org/10.1177/1932296818822496
96. Kweon M (2020) Medical nutrition therapy using continuous glucose monitoring system. J Korean Diabetes 21:216–220. https://doi.org/10.4093/jkd.2020.21.4.216
97. Soliman A et al (2014) Continuous glucose monitoring system and new era of early diagnosis of diabetes in high risk groups. Indian J Endocrinol Metab 18(3):274–282. https://doi.org/10.4103/2230-8210.131130
98. Rao H et al (2021) The use of continuous glucose monitoring in older people with type 2 diabetes. Sr Care Pharm 36(11):556–567. https://doi.org/10.4140/TCP.n.2021.556
99. Feig DS et al (2017) Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. Lancet 390(10110):2347–2359. https://doi.org/10.1016/s0140-6736(17)32400-5
100. Steck AK et al (2022) CGM metrics predict imminent progression to type 1 diabetes: autoimmunity screening for kids (ASK) study. Diabetes Care 45(2):365–371. https://doi.org/10.2337/dc21-0602
101. Steck AK et al (2019) Continuous glucose monitoring predicts progression to diabetes in autoantibody positive children. J Clin Endocrinol Metab 104(8):3337–3344. https://doi.org/10.1210/jc.2018-02196
102. Agarwal S et al (2021) Continuous glucose monitoring in the intensive care unit during the COVID-19 pandemic. Diabetes Care 44(3):847–849. https://doi.org/10.2337/dc20-2219
103. Perez-Guzman MC et al (2021) Continuous glucose monitoring in the operating room and cardiac intensive care unit. Diabetes Care 44(3):e50–e52. https://doi.org/10.2337/dc20-2386
104. Galindo RJ et al (2020) Implementation of continuous glucose monitoring in the hospital: emergent considerations for remote glucose monitoring during the COVID-19 pandemic. J Diabetes Sci Technol 14(4):822–832. https://doi.org/10.1177/1932296820932903
105. Gal RL et al (2020) Diabetes telehealth solutions: improving self-management through remote initiation of continuous glucose monitoring. J Endocr Soc 4(9):bvaa076. https://doi.org/10.1210/jendso/bvaa076
106. Burckhardt MA et al (2019) Use of remote monitoring with continuous glucose monitoring in young children with Type 1 diabetes: the parents' perspective. Diabet Med 36(11):1453–1459. https://doi.org/10.1111/dme.14061
107. Andrès E et al (2019) Telemonitoring in diabetes: evolution of concepts and technologies, with a focus on results of the more recent studies. J Med Life 12(3):203–214. https://doi.org/10.25122/jml-2019-0006
108. Hartman I (2008) Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence. Clin Med Res 6(2):54–67. https://doi.org/10.3121/cmr.2008.793
109. Walter HM, Timmler R, Mehnert H (1990) Stabilized human insulin prevents catheter occlusion during continuous subcutaneous insulin infusion. Diabetes Res 13(2):75–77
110. Nathan DM et al (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes Mellitus. N Engl J Med 329(14):977–986. https://doi.org/10.1056/nejm199309303291401
111. King P, Peacock I, Donnelly R (1999) The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol 48(5):643–648. https://doi.org/10.1046/j.1365-2125.1999.00092.x
112. Alsaleh FM et al (2010) Insulin pumps: from inception to the present and toward the future. J Clin Pharm Ther

ABBOTT Exhibit 2026, Page 20 of 26
Dexcom, Inc. v. Abbott Diabetes Care Inc.
IPR2023-01251

35(2):127–138. https://doi.org/10.1111/j.1365-2710.2009.01048.x

113. Fogt EJ et al (1978) Development and evaluation of a glucose analyzer for a glucose controlled insulin infusion system (Biostator). Clin Chem 24(8):1366–1372. https://doi.org/10.1093/clinchem/24.8.1366
114. Kesavadev J et al (2020) Evolution of insulin delivery devices: from syringes, pens, and pumps to DIY artificial pancreas. Diabetes Ther 11(6):1251–1269. https://doi.org/10.1007/s13300-020-00831-z
115. Weaver KW, Hirsch IB (2018) The hybrid closed-loop system: evolution and practical applications. Diabetes Technol Ther 20(S2):S216-s223. https://doi.org/10.1089/dia.2018.0091
116. Allen N, Gupta A (2019) Current diabetes technology: striving for the artificial pancreas. Diagnostics (Basel). https://doi.org/10.3390/diagnostics9010031
117. Tandem Diabetes Care I (2012) Tandem Diabetes Care Launches t:slim Insulin Delivery System, I. Tandem Diabetes Care, Editor. Tandem Diabetes Care, Inc
118. Schaeffer NE (2013) Human factors research applied: the development of a personal touch screen insulin pump and users' perceptions of actual use. Diabetes Technol Ther 15(10):845–854. https://doi.org/10.1089/dia.2013.0098
119. Zisser HC (2010) The OmniPod Insulin Management System: the latest innovation in insulin pump therapy. Diabetes Ther 1(1):10–24. https://doi.org/10.1007/s13300-010-0004-6
120. Dairman T (2009) Deltec Cozmo Pump Discontinued. https://www.diabetesselfmanagement.com/blog/deltec-cozmo-pump-discontinued/#:~:text=As%20Eric%20Lagergren%20mentioned%20in,ultimately%2C%20exiting%20the%20diabetes%20business
121. Companies JJDC (2017) Animas corporation to close operations and exit insulin pump market, J.J.D.C. Companies, Editor. Johnson & Johnson
122. Hoskins M (2018) NEWS: Roche hands over remaining U.S. insulin pump customers to Medtronic. https://www.healthline.com/diabetesmine/roche-hands-off-remaining-pump-customers-medtronic#2
123. Kaleido. https://www.hellokaleido.com/
124. SOOIL Development Co., L (2022) History. https://sooil.com/about/history.php
125. Company EL (2020) Lilly and Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes. 2020. https://investor.lilly.com/news-releases/news-release-details/lilly-and-ypsomed-collaborate-advance-automated-insulin-delivery
126. Gingras V et al (2016) Efficacy of dual-hormone artificial pancreas to alleviate the carbohydrate-counting burden of type 1 diabetes: a randomized crossover trial. Diabetes Metab 42(1):47–54. https://doi.org/10.1016/j.diabet.2015.05.001
127. El-Khatib FH et al (2017) Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial. Lancet 389(10067):369–380. https://doi.org/10.1016/s0140-6736(16)32567-3
128. Haidar A et al (2020) A novel dual-hormone insulin-and-pramlintide artificial pancreas for type 1 diabetes: a randomized controlled crossover trial. Diabetes Care 43(3):597–606. https://doi.org/10.2337/dc19-1922
129. Mastrototaro J, Lee S (2009) The integrated MiniMed Paradigm real-time insulin pump and glucose monitoring system: implications for improved patient outcomes. Diabetes Technol Ther 11(Suppl 1):S37-43. https://doi.org/10.1089/dia.2008.0134
130. Mastrototaro J et al (2008) The accuracy and efficacy of real-time continuous glucose monitoring sensor in patients with type 1 diabetes. Diabetes Technol Ther 10:385
131. Agrawal P et al (2011) Usage and effectiveness of the low glucose suspend feature of the Medtronic Paradigm Veo insulin pump. J Diabetes Sci Technol 5(5):1137–1141. https://doi.org/10.1177/193229681100500514
132. Therapeutics, T.M.L.o.D.a. (2015) MiniMed 530G: an insulin pump with low-glucose suspend automation. JAMA 313(15):1568–1568. https://doi.org/10.1001/jama.2015.2917
133. Garg S et al (2012) Reduction in duration of hypoglycemia by automatic suspension of insulin delivery: the in-clinic ASPIRE study. Diabetes Technol Ther 14(3):205–209. https://doi.org/10.1089/dia.2011.0292
134. Brazg RL et al (2011) The ASPIRE study: design and methods of an in-clinic crossover trial on the efficacy of automatic insulin pump suspension in exercise-induced hypoglycemia. J Diabetes Sci Technol 5(6):1466–1471. https://doi.org/10.1177/193229681100500621
135. Klonoff DC et al (2013) ASPIRE In-Home: rationale, design, and methods of a study to evaluate the safety and efficacy of automatic insulin suspension for nocturnal hypoglycemia. J Diabetes Sci Technol 7(4):1005–1010. https://doi.org/10.1177/193229681300700424
136. Bergenstal RM et al (2013) Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med 369(3):224–232. https://doi.org/10.1056/NEJMoa1303576
137. Zhong A et al (2016) Effectiveness of automated insulin management features of the MiniMed 640G sensor-augmented insulin pump. Diabetes Technol Ther 18(10):657–663. https://doi.org/10.1089/dia.2016.0216
138. Buckingham BA et al (2017) Evaluation of a predictive low-glucose management system in-clinic. Diabetes Technol Ther 19(5):288–292. https://doi.org/10.1089/dia.2016.0319
139. Saunders A, Messer LH, Forlenza GP (2019) MiniMed 670G hybrid closed loop artificial pancreas system for the treatment of type 1 diabetes mellitus: overview of its safety and efficacy. Expert Rev Med Devices 16(10):845–853. https://doi.org/10.1080/17434440.2019.1670639

ABBOTT Exhibit 2026, Page 21 of 26
Dexcom, Inc. v. Abbott Diabetes Care Inc.
IPR2023-01251

140. Bergenstal RM et al (2016) Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA 316(13):1407–1408. https://doi.org/10.1001/jama.2016.11708
141. Garg SK et al (2017) Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther 19(3):155–163. https://doi.org/10.1089/dia.2016.0421
142. Messer LH, Berget C, Forlenza GP (2019) A clinical guide to advanced diabetes devices and closed-loop systems using the CARES paradigm. Diabetes Technol Ther 21(8):462–469. https://doi.org/10.1089/dia.2019.0105
143. Zhou K, Isaacs D (2022) Closed-loop artificial pancreas therapy for type 1 diabetes. Curr Cardiol Rep. https://doi.org/10.1007/s11886-022-01733-1
144. Boughton CK, Hovorka R (2021) New closed-loop insulin systems. Diabetologia 64(5):1007–1015. https://doi.org/10.1007/s00125-021-05391-w
145. Forlenza GP et al (2019) Safety evaluation of the MiniMed 670G system in children 7–13 years of age with type 1 diabetes. Diabetes Technol Ther 21(1):11–19. https://doi.org/10.1089/dia.2018.0264
146. Knebel T, Neumiller JJ (2019) Medtronic MiniMed 670G hybrid closed-loop system. Clin Diabetes 37(1):94–95. https://doi.org/10.2337/cd18-0067
147. Nimri R et al (2021) Feasibility study of a hybrid closed-loop system with automated insulin correction boluses. Diabetes Technol Ther 23(4):268–276. https://doi.org/10.1089/dia.2020.0448
148. Carlson AL et al (2022) Safety and glycemic outcomes during the MiniMed™ advanced hybrid closed-loop system pivotal trial in adolescents and adults with type 1 diabetes. Diabetes Technol Ther 24(3):178–189. https://doi.org/10.1089/dia.2021.0319
149. Bergenstal RM et al (2021) A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial. Lancet 397(10270):208–219. https://doi.org/10.1016/s0140-6736(20)32514-9
150. Silva JD et al (2022) Real-world performance of the MiniMed™ 780G system: first report of outcomes from 4120 users. Diabetes Technol Ther 24(2):113–119. https://doi.org/10.1089/dia.2021.0203
151. Collyns OJ et al (2021) Improved glycemic outcomes with medtronic MiniMed advanced hybrid closed-loop delivery: results from a randomized crossover trial comparing automated insulin delivery with predictive low glucose suspend in people with type 1 diabetes. Diabetes Care 44(4):969–975. https://doi.org/10.2337/dc20-2250
152. Messer LH et al (2021) Basal-IQ technology in the real world: satisfaction and reduction of diabetes burden in individuals with type 1 diabetes. Diabet Med 38(6):e14381. https://doi.org/10.1111/dme.14381
153. Pinsker JE et al (2021) Real-world patient-reported outcomes and glycemic results with initiation of control-IQ technology. Diabetes Technol Ther 23(2):120–127. https://doi.org/10.1089/dia.2020.0388
154. Forlenza GP et al (2018) Predictive low-glucose suspend reduces hypoglycemia in adults, adolescents, and children with type 1 diabetes in an at-home randomized crossover study: results of the PROLOG trial. Diabetes Care 41(10):2155–2161. https://doi.org/10.2337/dc18-0771
155. Breton MD, Kovatchev BP (2021) One year real-world use of the control-IQ advanced hybrid closed-loop technology. Diabetes Technol Ther 23(9):601–608. https://doi.org/10.1089/dia.2021.0097
156. Brown S et al (2018) First look at control-IQ: a new-generation automated insulin delivery system. Diabetes Care 41(12):2634–2636. https://doi.org/10.2337/dc18-1249
157. Ekhlaspour L et al (2021) Safety and performance of the tandem t:slim X2 with control-IQ automated insulin delivery system in toddlers and preschoolers. Diabetes Technol Ther 23(5):384–391. https://doi.org/10.1089/dia.2020.0507
158. Brown SA et al (2019) Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med 381(18):1707–1717. https://doi.org/10.1056/NEJMoa1907863
159. Forlenza GP et al (2019) Successful at-home use of the tandem control-IQ artificial pancreas system in young children during a randomized controlled trial. Diabetes Technol Ther 21(4):159–169. https://doi.org/10.1089/dia.2019.0011
160. Bassi M et al (2021) A comparison of two hybrid closed-loop systems in Italian children and adults with type 1 diabetes. Front Endocrinol (Lausanne) 12:802419. https://doi.org/10.3389/fendo.2021.802419
161. Buckingham BA et al (2018) Safety and feasibility of the OmniPod hybrid closed-loop system in adult, adolescent, and pediatric patients with type 1 diabetes using a personalized model predictive control algorithm. Diabetes Technol Ther 20(4):257–262. https://doi.org/10.1089/dia.2017.0346
162. Forlenza GP et al (2021) First outpatient evaluation of a tubeless automated insulin delivery system with customizable glucose targets in children and adults with type 1 diabetes. Diabetes Technol Ther 23(6):410–424. https://doi.org/10.1089/dia.2020.0546
163. Brown SA et al (2021) Multicenter trial of a tubeless, on-body automated insulin delivery system with customizable glycemic targets in pediatric and adult participants with type 1 diabetes. Diabetes Care 44(7):1630–1640. https://doi.org/10.2337/dc21-0172
164. Forlenza GP et al (2019) Performance of omnipod personalized model predictive control algorithm with moderate intensity exercise in adults with type 1

ABBOTT Exhibit 2026, Page 22 of 26
Dexcom, Inc. v. Abbott Diabetes Care Inc.
IPR2023-01251

diabetes. Diabetes Technol Ther 21(5):265–272. https://doi.org/10.1089/dia.2019.0017

165. Sherr JL et al (2022) Safety and glycemic outcomes with a tubeless automated insulin delivery system in very young children with type 1 diabetes: a single-arm multicenter clinical trial. Diabetes Care. https://doi.org/10.2337/dc21-2359
166. JDRF (2022) FDA Authorizes Omnipod 5 for Ages 2+ in Children with Type 1 Diabetes
167. Amadou C et al (2021) Diabeloop DBLG1 closed-loop system enables patients with type 1 diabetes to significantly improve their glycemic control in real-life situations without serious adverse events: 6-month follow-up. Diabetes Care 44(3):844–846. https://doi.org/10.2337/dc20-1809
168. Thabit H et al (2015) Home use of an artificial beta cell in type 1 diabetes. N Engl J Med 373(22):2129–2140. https://doi.org/10.1056/NEJMoa1509351
169. Tauschmann M et al (2018) Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. Lancet 392(10155):1321–1329. https://doi.org/10.1016/s0140-6736(18)31947-0
170. Lewis DM (2020) Do-it-yourself artificial pancreas system and the OpenAPS movement. Endocrinol Metab Clin North Am 49(1):203–213. https://doi.org/10.1016/j.ecl.2019.10.005
171. Kesavadev J et al (2020) The do-it-yourself artificial pancreas: a comprehensive review. Diabetes Ther 11(6):1217–1235. https://doi.org/10.1007/s13300-020-00823-z
172. Oliver N et al (2019) Open source automated insulin delivery: addressing the challenge. NPJ Digit Med 2:124. https://doi.org/10.1038/s41746-019-0202-1
173. Lewis DM, Hussain S (2022) Practical guidance on open source and commercial automated insulin delivery systems: a guide for healthcare professionals supporting people with insulin-requiring diabetes. Diabetes Ther 13(9):1683–1699. https://doi.org/10.1007/s13300-022-01299-9
174. Crabtree TSJ et al (2022) Association of British clinical diabetologists, diabetes technology network UK and Association of Children's Diabetes Clinicians Survey of UK Healthcare professional attitudes towards open-source automated insulin delivery systems. Diabetes Ther 13(2):341–353. https://doi.org/10.1007/s13300-022-01203-5
175. Petrovski G et al (2021) One-year experience of hybrid closed-loop system in children and adolescents with type 1 diabetes previously treated with multiple daily injections: drivers to successful outcomes. Acta Diabetol 58(2):207–213. https://doi.org/10.1007/s00592-020-01607-4
176. Tornese G et al (2021) Six-month effectiveness of advanced vs. standard hybrid closed-loop system in children and adolescents with type 1 diabetes Mellitus. Front Endocrinol (Lausanne) 12:766314. https://doi.org/10.3389/fendo.2021.766314
177. Janez A et al (2021) Hybrid closed-loop systems for the treatment of type 1 diabetes: a collaborative, expert group position statement for clinical use in central and eastern Europe. Diabetes Ther 12(12):3107–3135. https://doi.org/10.1007/s13300-021-01160-5
178. Moreno-Fernández J, García-Seco JA (2021) Commercialized hybrid closed-loop system (Minimed Medtronic 670G) results during pregnancy. AACE Clin Case Rep 7(3):177–179. https://doi.org/10.1016/j.aace.2020.11.039
179. Feig DS et al (2018) Pumps or multiple daily injections in pregnancy involving type 1 diabetes: a prespecified analysis of the CONCEPTT randomized trial. Diabetes Care 41(12):2471–2479. https://doi.org/10.2337/dc18-1437
180. Guzmán Gómez GE et al (2021) The closed-loop system improved the control of a pregnant patient with type 1 diabetes Mellitus. Case Rep Endocrinol 2021:7310176. https://doi.org/10.1155/2021/7310176
181. Gildon BW (2018) InPen smart insulin pen system: product review and user experience. Diabetes Spectr 31(4):354–358. https://doi.org/10.2337/ds18-0011
182. (2020) Companion Medical InPen Receives FDA Clearance for Expanded Pediatric Use. https://www.prnewswire.com/news-releases/companion-medical-inpen-receives-fda-clearance-for-expanded-pediatric-use-301081939.html#:~:text=Now%20that%20InPen%20is%20approved,to%20manage%20their%20children's%20diabetes
183. Kompala T, Neinstein AB (2022) Smart insulin pens: advancing digital transformation and a connected diabetes care ecosystem. J Diabetes Sci Technol 16(3):596–604. https://doi.org/10.1177/1932296820984490
184. Klonoff DC, Kerr D (2018) Smart pens will improve insulin therapy. J Diabetes Sci Technol 12(3):551–553. https://doi.org/10.1177/1932296818759845
185. Galindo RJ et al (2021) Efficacy of a smart insulin pen cap for the management of patients with uncontrolled type 2 diabetes: a randomized cross-over trial. J Diabetes Sci Technol. https://doi.org/10.1177/19322968211033837
186. Sangave NA, Aungst TD, Patel DK (2019) Smart connected insulin pens, caps, and attachments: a review of the future of diabetes technology. Diabetes Spectr 32(4):378–384. https://doi.org/10.2337/ds18-0069
187. Rodbard D, Garg SK (2021) Standardizing reporting of glucose and insulin data for patients on multiple daily injections using connected insulin pens and continuous glucose monitoring. Diabetes Technol Ther 23(3):221–226. https://doi.org/10.1089/dia.2021.0030
188. Bergenstal RM et al (2013) Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the

ABBOTT Exhibit 2026, Page 23 of 26
Dexcom, Inc. v. Abbott Diabetes Care Inc.
IPR2023-01251

Ambulatory Glucose Profile (AGP). Diabetes Technol Ther 15(3):198–211. https://doi.org/10.1089/dia.2013.0051
189. Shah VN, Garg SK (2021) Standardized hybrid closed-loop system reporting. Diabetes Technol Ther 23(5):323–331. https://doi.org/10.1089/dia.2020.0622
190. Melillo G (2021) FDA clears bigfoot BioMedical's smart insulin pen caps. https://www.ajmc.com/view/fda-clears-bigfoot-biomedical-s-smart-insulin-pen-caps
191. Younk LM et al (2011) Exercise-related hypoglycemia in diabetes mellitus. Expert Rev Endocrinol Metab 6(1):93–108. https://doi.org/10.1586/eem.10.78
192. Castle JR (2018) Is mini-dose glucagon the answer to preventing exercise-related dysglycemia? Diabetes Care 41(9):1842–1843. https://doi.org/10.2337/dci18-0024
193. Chung ST, Haymond MW (2015) Minimizing morbidity of hypoglycemia in diabetes: a review of mini-dose glucagon. J Diabetes Sci Technol 9(1):44–51. https://doi.org/10.1177/1932296814547518
194. Basu R et al (2014) Exercise, hypoglycemia, and type 1 diabetes. Diabetes Technol Ther 16(6):331–337. https://doi.org/10.1089/dia.2014.0097
195. Wilson LM, Jacobs PG, Castle JR (2020) Role of glucagon in automated insulin delivery. Endocrinol Metab Clin North Am 49(1):179–202. https://doi.org/10.1016/j.ecl.2019.10.008
196. Wilson LM et al (2020) Dual-hormone closed-loop system using a liquid stable glucagon formulation versus insulin-only closed-loop system compared with a predictive low glucose suspend system: an open-label, outpatient, single-center, crossover, randomized controlled trial. Diabetes Care 43(11):2721–2729. https://doi.org/10.2337/dc19-2267
197. Pharma Z (2019) Beta Bionics and Zealand Pharma initiate home-use trial of the iLet™ bionic pancreas with dasiglucagon for autonomous bihormonal treatment of Type 1 diabetes Z. Pharma, Editor
198. Russell SJ et al (2014) Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med 371(4):313–325. https://doi.org/10.1056/NEJMoa1314474
199. Tauschmann M, Hovorka R (2018) Technology in the management of type 1 diabetes mellitus—current status and future prospects. Nat Rev Endocrinol 14(8):464–475. https://doi.org/10.1038/s41574-018-0044-y
200. Group., B.P.R. et al (2022) Multicenter, randomized trial of a bionic pancreas in type 1 diabetes. New England J Med 387(13):1161–1172
201. Group., B.P.R. et al (2022) A multicenter randomized trial evaluating the insulin-only configuration of the bionic pancreas in adults with type 1 diabetes. Diabetes Technol Ther. https://doi.org/10.1089/dia.2022.0200
202. Group., B.P.R. et al (2022) Positive impact of the bionic pancreas on diabetes control in youth 6–17 years old with type 1 diabetes: a multicenter randomized trial. Diabetes Technol Ther. https://doi.org/10.1089/dia.2022.0201
203. Group., B.P.R. et al (2022) A multicenter randomized trial evaluating fast-acting insulin Aspart in the bionic pancreas in adults with type 1 diabetes. Diabetes Technol Therapeutics. https://doi.org/10.1089/dia2022.0167
204. Group., B.P.R. et al (2022) The insulin-only bionic pancreas pivotal trial extension study: a multi-center single-arm evaluation of the insulin-only configuration of the bionic pancreas in adults and youth with type 1 diabetes. Diabet Technol Ther. https://doi.org/10.1089/dia2022.0341
205. Tsoukas MA et al (2021) Alleviating carbohydrate counting with a FiASP-plus-pramlintide closed-loop delivery system (artificial pancreas): Feasibility and pilot studies. Diabetes Obes Metab 23(9):2090–2098. https://doi.org/10.1111/dom.14447
206. Weinzimer SA et al (2012) Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes. Diabetes Care 35(10):1994–1999. https://doi.org/10.2337/dc12-0330
207. Sherr JL et al (2016) Mitigating meal-related glycemic excursions in an insulin-sparing manner during closed-loop insulin delivery: the beneficial effects of adjunctive pramlintide and liraglutide. Diabetes Care 39(7):1127–1134. https://doi.org/10.2337/dc16-0089
208. Ratner RE et al (2004) Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med 21(11):1204–1212. https://doi.org/10.1111/j.1464-5491.2004.01319.x
209. Heptulla RA et al (2005) The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes. Diabetes 54(4):1100–1107. https://doi.org/10.2337/diabetes.54.4.1100
210. Wigley FM et al (1971) Insulin across respiratory mucosae by aerosol delivery. Diabetes 20(8):552–556. https://doi.org/10.2337/diab.20.8.552
211. Elliott RB et al (1987) Parenteral absorption of insulin from the lung in diabetic children. Aust Paediatr J 23(5):293–297. https://doi.org/10.1111/j.1440-1754.1987.tb00275.x
212. Alabraba V et al (2009) Exubera inhaled insulin in patients with type 1 and type 2 diabetes: the first 12 months. Diabetes Technol Ther 11(7):427–430. https://doi.org/10.1089/dia.2008.0131
213. Administration, U.S.F.a.D. (2006) Exubera (insulin human [rDNA origin] inhalation powder) and Exubera Inhaler: Company: Pfizer Global Research & Development. NDA: 021868 Approval Date: 1/27/2006]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021868_exubera_toc.cfm
214. Oleck J, Kassam S, Goldman JD (2016) Commentary: why was inhaled insulin a failure in the market? Diabetes Spectr 29(3):180–184. https://doi.org/10.2337/diaspect.29.3.180

ABBOTT Exhibit 2026, Page 24 of 26
Dexcom, Inc. v. Abbott Diabetes Care Inc.
IPR2023-01251

215. Akturk HK et al (2018) Improved postprandial glucose with inhaled technosphere insulin compared with insulin Aspart in patients with type 1 diabetes on multiple daily injections: the STAT study. Diabetes Technol Ther 20(10):639–647. https://doi.org/10.1089/dia.2018.0200
216. Rave K et al (2009) Pharmacokinetics and linear exposure of AFRESA™ compared with the subcutaneous injection of regular human insulin. Diabetes Obes Metab 11(7):715–720. https://doi.org/10.1111/j.1463-1326.2009.01039.x
217. Rave K et al (2008) Inhaled technosphere insulin in comparison to subcutaneous regular human insulin: time action profile and variability in subjects with type 2 diabetes. J Diabetes Sci Technol 2(2):205–212. https://doi.org/10.1177/193229680800200206
218. Bode BW et al (2015) Inhaled technosphere insulin compared with injected prandial insulin in type 1 diabetes: a randomized 24-week trial. Diabetes Care 38(12):2266–2273. https://doi.org/10.2337/dc15-0075
219. Rosenstock J et al (2015) Inhaled technosphere insulin versus inhaled technosphere placebo in insulin-naïve subjects with type 2 diabetes inadequately controlled on oral antidiabetes agents. Diabetes Care 38(12):2274–2281. https://doi.org/10.2337/dc15-0629
220. Zisser H et al (2015) Clinical results of an automated artificial pancreas using technosphere inhaled insulin to mimic first-phase insulin secretion. J Diabetes Sci Technol 9(3):564–572. https://doi.org/10.1177/1932296815582061
221. Garg SK, Strumph P (2018) Effects of sotagliflozin added to insulin in type 1 diabetes. N Engl J Med 378(10):967–968. https://doi.org/10.1056/NEJMc1800394
222. Huang Y, Jiang Z, Wei Y (2021) Efficacy and safety of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a meta-analysis of randomized controlled trials. Exp Ther Med 21(4):382. https://doi.org/10.3892/etm.2021.9813
223. Chen HY et al (2020) The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study. Cardiovasc Diabetol 19(1):73. https://doi.org/10.1186/s12933-020-01048-x
224. Chung M-C et al (2021) Association of sodium-glucose transport protein 2 inhibitor use for type 2 diabetes and incidence of gout in Taiwan. JAMA Netw Open 4(11):e2135353–e2135353. https://doi.org/10.1001/jamanetworkopen.2021.35353
225. Monami M, Nardini C, Mannucci E (2014) Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 16(5):457–466. https://doi.org/10.1111/dom.12244
226. Zinman B et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117–2128. https://doi.org/10.1056/NEJMoa1504720
227. Teymourian H et al (2020) Microneedle-based detection of ketone bodies along with glucose and lactate: toward real-time continuous interstitial fluid monitoring of diabetic ketosis and ketoacidosis. Anal Chem 92(2):2291–2300. https://doi.org/10.1021/acs.analchem.9b05109
228. Zimmerman C, Albanese-O'Neill A, Haller MJ (2019) Advances in type 1 diabetes technology over the last decade. Eur Endocrinol 15(2):70–76. https://doi.org/10.17925/ee.2019.15.2.70
229. Eiland L, Thangavelu T, Drincic A (2019) Has technology improved diabetes management in relation to age, gender, and ethnicity? Curr Diab Rep 19(11):111. https://doi.org/10.1007/s11892-019-1231-5
230. Bratke H et al (2021) Does current diabetes technology improve metabolic control? A cross-sectional study on the use of insulin pumps and continuous glucose monitoring devices in a nationwide pediatric population. Diabetes Ther 12(9):2571–2583. https://doi.org/10.1007/s13300-021-01127-6
231. Bailey TS, Walsh J, Stone JY (2018) Emerging technologies for diabetes care. Diabetes Technol Ther 20(S2):S278-s284. https://doi.org/10.1089/dia.2018.0115

Abdulhalim M. Almurashi is a consultant of diabetes and family medicine in Madinah Health Cluster, Madinah, Saudi Arabia since 2021. He is a member of The American Diabetes Association. Dr. Almurashi received a medical degree in medicine at Taibah University in Madinah, Saudi Arabia. He completed his residency in family medicine at King Salman Armed Forced Hospital in Tabuk, Saudi Arabia. He then completed a fellowship in adult diabetes at the King Abdulaziz Medical City in Jeddah, Saudi Arabia. In 2022, Dr. Almurashi completed a diabetes technology fellowship at the Barbara Davis Diabetes Center of the University of Colorado School of Medicine in Denver, Colorado.

Erika Rodriguez is a senior clinical research professional in the Pediatric Clinic at the Barbara Davis Center (BDC) for Diabetes of the University of Colorado School of Medicine in Denver, Colorado. Erika is currently working within the BDC Latino Program which focuses on equitable access to diabetes technology and therapeutics for Spanish-speaking communities. Erika received a bachelor's in Behavioral Biology from Johns Hopkins University, Baltimore, Maryland and a master's degree in Biomedical Sciences from Regis University, Denver, Colorado.

ABBOTT Exhibit 2026, Page 25 of 26
Dexcom, Inc. v. Abbott Diabetes Care Inc.
IPR2023-01251

Satish K. Garg is Professor of Medicine and Pediatrics at the Adult Clinic of the Barbara Davis Center for Diabetes of the University of Colorado School of Medicine in Denver, Colorado. He joined the faculty of the Barbara Davis Center in 1992 and became the founder and director of the Adult Clinic. He established and holds two Garg Endowed Chairs (clinical and clinical research) at the University of Colorado Denver. His team is one of the top teams world-wide in clinical trials involving insulin analogues and novel methods of insulin delivery (pens, pumps, oral, buccal and inhaled) and non-insulin adjunctive treatment options for Type 1 Diabetes. Other areas of interest include continuous glucose monitors, evaluating the accuracy of meters at high altitude, and artificial pancreas systems. Dr. Garg received a medical degree in medicine at Punjab University in Ludhiana, India, where he also completed a residency in internal medicine at Christian Medical College and Hospital. He completed fellowships in adult endocrinology and diabetes at the Post Graduate Institute of Medical Education and Research (PGIMER) in Chandigarh, India, and in pediatric endocrinology and diabetes at the University of Colorado at Denver and Health Sciences Center. He is board certified in internal medicine and endocrinology and diabetes. Dr. Garg is the Editor in chief of Diabetes Technology and Therapeutics journal since 2006 and Chair of the planning committee for Clinical Therapeutics and New Technology area for 2007 and 2008 Annual American Diabetes Associations meetings. He is the director of ATDC Diabetes Conference, in Keystone, since 2005 and helps coordinate 1-year Diabetes Fellowship at BDC/UCD. He is a member of the many Endocrine and Diabetes Societies such as: International Diabetes Federation, the American Diabetes Association, the Endocrine Society of India, and the European Association of Study for Diabetes, the Regional Pediatric Endocrine Society of Colorado, the Research Society for Study of Diabetes Mellitus, and numerous other professional societies in both the United States and India. He is an international lecturer and speaker—he received several international oration awards—and has published many chapters in the books, on the editorial boards for many of the diabetes journals globally and has published more than 332 original manuscripts in peer-review journals.

ABBOTT Exhibit 2026, Page 26 of 26
Dexcom, Inc. v. Abbott Diabetes Care Inc.
IPR2023-01251